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There is a high prevalence of gestational diabetes (GD) in South Africa, which is continually 
growing. South African women with GD are not effectively managed or educated about self-
care, do not self-monitor frequently enough and, therefore, often succumb to various GD 
induced complications. The ineffective management of GD is largely due to financial and time 
constraints caused by the regularly required outpatient services. On the other hand, 
healthcare professionals do not monitor their patients frequently enough because of 
accessibility issues, which means they cannot intervene timeously to prevent diabetes 
complications. 
The aim of this project was to develop a mobile health (mHealth) platform for GD self-
management and for remote monitoring to improve the GD cycle of care in South Africa. The 
objectives were to assess the current GD management practices in South Africa, to assess the 
existing mHealth solutions for GD and to design, develop and test a GD mHealth platform. 
The existing GD management practices and current GD mHealth solutions were investigated. 
The results of the investigation informed the design of low-fidelity and high-fidelity mock-ups 
of the platform. The high-fidelity mock-up underwent usability testing and the insights gained 
were used to develop a working prototype of the new mHealth platform, which was then 
ready for in-lab testing. 
It was found that GD had a prevalence of up to 25% in parts of South Africa. Over 70% of 
patients in both private and public healthcare sectors did not meet their diabetic goals, which 
directly correlated with diabetes induced complications. However, previous research found 
that using mHealth as an intervention caused a statistically significant decrease of 0.38 
mmol/L (95% confidence interval (CI) 0.52 mmol/L to 0.23 mmol/L) in overall blood glucose 
levels during pregnancy when compared to a control group. There was a higher probability of 
vaginal deliveries in the intervention group than in the control group (risk ratio = 1.18). It was 
less likely for new-borns from the intervention group to be diagnosed with hypoglycaemia 
than new-borns from the control group (risk ratio = 0.67).  
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Based on the research and usability studies conducted, an alpha version of the GD mHealth 
platform was developed, including a mobile app used to track the patient’s blood glucose 
levels via a Bluetooth-enabled glucose meter. The food intake, exercise and weight gain 
during pregnancy were manually captured by the patient. The app reminded the patient to 
take medication, measure glucose levels and attend appointments. A GD educational 
component was available for the patient throughout the pregnancy. The platform included a 
web app which allowed healthcare professionals to remotely monitor and communicate with 
their patients so that they could analyse trends in the data and intervene when necessary.  
The testing done on the prototype resulted in positive feedback with 60% of participants 
saying that they would use the GooDMoM mobile app to manage their GD and 70% of 
participants saying that they would use the GooDMoM web app to manage their patients with 
GD. This put the platform in a good position for beta development. 
The solution has the potential to benefit patients both financially and timewise, by reducing 
the frequency of hospital visits required. It also has the potential to positively impact the 
healthcare professionals by reducing the tediousness of their workload and allowing for 
remote monitoring of patients. The platform can, thus, optimise the GD management process 
in South Africa and worldwide. 
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This chapter introduces the topic of the thesis by highlighting the background of the problem 
and providing a detailed synopsis of the problem, rationale, aim, objectives and methodology. 
The chapter concludes with the presentation of the thesis’ structure. 
1.1. Background 
Diabetes is a chronic, non-communicable condition which affects the body’s ability to process 
glucose (American Diabetes Association, 2014). Glucose is a type of sugar, which is broken 
down from dietary intake and transported in the blood stream to the necessary cells in the 
human body (Diabetes UK, 2006). The pancreas releases insulin into the blood stream on 
demand to regulate the amount of glucose in the blood (Diabetes UK, 2006). The vast majority 
of diabetes cases fall under three categories: type 1 diabetes (T1D), type 2 diabetes (T2D) and 
gestational diabetes (GD) (Lanzola et al., 2016). GD arises during pregnancy and increases the 
risk of complications for both the mother and child before, during and after birth 
(Garnweidner-Holme et al., 2015). It has been shown to have a prevalence of up to 25% in 
parts of South Africa according to Adams & Rheeder (2017). However, this prevalence varies 
depending on screening methods, diagnostic criteria and the ethnic group involved in the 
study. 
Once diagnosed, controlling blood glucose levels becomes a fundamental part of the 
management of GD (Kampmann et al., 2015). Eating healthily, exercising regularly, managing 
bodyweight and learning about one’s disease are key to controlling blood glucose levels 
(Garnweidner-Holme et al., 2015). In some cases, insulin or oral medication may be necessary 
to aid the control of blood glucose levels (Kampmann et al., 2015). This means that women 
with GD need to track their glucose levels, food intake, exercise and weight throughout the 
gestational period and beyond (Buchanan, Xiang & Page, 2012). 
Women diagnosed with GD are encouraged to record their blood glucose levels at least 3 to 
4 times daily – once in the morning and after meals – either in a paper or digital logbook 
(Nhlapo, 2015). Delivering these measurements along with related alerts to healthcare 
professionals is important because this is the information that healthcare professionals use 
to manage and monitor their patients, which may include providing advice, modifying 
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medication or making diagnoses (Lanzola et al., 2016). Thus, regular medical check-ups are 
required for the healthcare professional to analyse the patient’s blood glucose levels, and 
these occur every 1 to 4 weeks during the last 3 months of gestation (Mackillop et al., 2018). 
According to a study done by the Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA) (2017), 9.5% of South Africans older than 15 are known to suffer from 
diabetes which is expected to increase by 140% by 2040. The most recently released mortality 
report from Statistics South Africa (2016a) shows that diabetes (5.5% mortality) has surpassed 
HIV/Aids (4.8% mortality) as the second highest cause of death in South Africa. On top of the 
list of natural diseases causing mortality is Tuberculosis (6.5% mortality). The high prevalence 
of diabetes combined with the increasing prevalence of obesity in women of a child-bearing 
age has resulted in a rapid rise in the prevalence of GD both worldwide and in South Africa 
(Kampmann et al., 2015). If this condition is poorly managed or is left untreated, women and 
their children will be at an increased risk of complications, before during and after birth 
(Kampmann et al., 2015).  
Lau et al. (2016), Ming et al. (2016) and Rasekaba et al. (2015) have systematically reviewed 
various studies which indicate that mHealth may aid in the management of women with GD, 
which helps keep tighter glycaemic control and assists in preventing antenatal, perinatal and 
postpartum complications. Although these studies involved high-income countries, the 
principles of mHealth being used to aid the management of GD can be applied to low and 
middle-income countries (LMIC) like South Africa. According to Barron et al. (2018), South 
Africa has universal mobile phone penetration, 40% of which is smartphone use. As a result 
of this, mHealth can be used to aid the ongoing management required for GD in South Africa.  
The major benefit offered by mHealth is the potential for remote diagnosis, monitoring and 
treatment (Bloomfield et al., 2014). This is especially important in LMIC like South Africa 
where it is not possible to access the entire population through physical healthcare 
institutions due to a lack of resources and the difficulty experienced by people in rural areas 
to access specialised healthcare services situated in urban areas as a result of high transport 
costs (Goldenberg et al., 2016). Thus, mHealth provides an inexpensive, more effective 
solution to the GD management problem (Lau et al., 2016).  
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1.2. Problem Statement 
There is a high prevalence of GD in South Africa, which is continually increasing. South African 
women with GD are not effectively managed or educated about self-care, do not self-monitor 
frequently enough and, therefore, often succumb to various GD induced complications. The 
ineffective management of GD is largely due to financial and time constraints caused by the 
regularly required outpatient services. On the other hand, healthcare professionals do not 
monitor their patients frequently enough because of accessibility issues, which means they 
cannot intervene timeously to prevent diabetes complications. 
1.3. Rationale 
A diabetes self-management and remote monitoring mobile platform can be used for GD 
educational purposes, it can be used to track the various indicators (blood glucose levels, 
medication, exercise, food intake, weight gain and pregnancy specific indicators, among 
others) and it can be used by healthcare professionals to remotely monitor their patients. This 
will aid in the management of GD and may positively affect the patient’s blood glucose levels 
and reduce the chance of GD induced complications. Pregnant women are easy to reach 
regarding health related information due to the regular contact they have with healthcare 
professionals and they are motivated for behavioural changes (Garnweidner-Holme et al., 
2015). This means that they will likely be willing to utilise an mHealth platform as a tool to 
manage GD. The mHealth platform has secondary benefits in that it will reduce the frequency 
of outpatient services (Mackillop et al., 2018) and will, therefore, reduce the financial burden 
which results from transport costs. 
The purpose of this project is to develop an easily accessible solution to the GD management 
problem facing pregnant South African women. There are three main components needed to 
fulfil the purpose; namely, to assess the current diabetes management practices in South 
Africa, to assess the existing mHealth solutions for GD and to design, develop and test the 
mHealth platform. The mHealth platform will consist of a mobile application (mobile app) for 
women with GD to manage their disease, a web application (web app) for healthcare 
professionals to remotely monitor their patients and the ability to wirelessly interface with 
Bluetooth-enabled glucose meters. 
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1.4. Aim and Objectives 
This sub-section presents the aim of the thesis and the objectives required to meet that aim.  
1.4.1. Aim 
The aim is to develop an mHealth platform for GD self-management and for remote 
monitoring by health professionals to improve the cycle of care in South Africa. 
1.4.2. Objectives  
The objectives required to meet the aim are: 
 to assess the current GD management practices in South Africa, focusing on: 
o GD epidemiology, complications and management practices, and 
o the effect that the public and private healthcare sectors have on the diabetes 
management practices. 
 to assess the existing mHealth solutions for GD, focusing on: 
o the benefits and challenges of mHealth, 
o the effectiveness of mHealth applied to women with GD in comparison to 
standard GD management practices, and 
o the features and functions of existing GD mHealth platforms. 
 to design, develop and test the mHealth platform for GD self-management and 
remote monitoring in South Africa, focusing on: 
o the development of software for women with GD to manage their disease, 
o the development of software for healthcare professionals to remotely monitor 
their patients, 
o the interface between the software and existing glucose meters, and 
o the testing of the developed platform. 
  




This section details the methodology that was followed in order to develop a GD self-
management and remote monitoring mobile platform.  
Figure 1.1 summarises the methodology in a flow diagram. This diagram integrates into the 
software development lifecycle (analyse, design, develop, test, deploy and maintain (Bassil, 
2012)) by ending in the testing phase (with an alpha version of the platform).  
 
Figure 1.1: Methodology flow diagram 
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1.5.1. Assessment of Gestational Diabetes Management Practices in South Africa 
The literature relating to the GD management practices in South Africa was reviewed using 
the Google Scholar database in the form of a narrative literature review. The review was 
performed in order to determine the problem and the need that should be addressed in order 
to develop a successful solution. Input from GD experts was included in the assessment of 
diabetes management practices in South Africa. 
The literature was used to create a flow diagram illustrating the GD cycle of care in South 
Africa and its related shortcomings. The mHealth platform was developed to optimise the 
cycle of care and improve the management practices. The platform incorporated the standard 
GD management practices so that it met professional medical standards in South Africa. 
1.5.2. Assessment of Existing mHealth Platforms for Gestational Diabetes 
The existing mHealth platforms for GD were assessed by broadly using systematic review 
procedures. Meta-analysis was performed, using Review Manager (RevMan Version 5.3), to 
analyse data from the included studies in order to determine whether mHealth was more 
effective than standard care in the management of GD. The features and functions required 
for a GD mHealth platform were extracted from the included studies. 
1.5.3. Design, Development and Testing of a Gestational Diabetes mHealth Platform 
Figure 1.2 diagrammatically depicts the network architecture of the platform. It shows that 
the mobile app is for patients and the web app is for healthcare professionals. The 
architecture is split into two major sections: the frontend (mobile app and web app) and the 
backend. The design and development of each section are discussed separately. 




Figure 1.2: mHealth platform architecture 
Prior to the commencement of the design phase, a software requirements specification 
document (SRSD) was collated. This document formalised the conceptual idea from the 
problem statement and rationale, providing a clear overview of the scope of the work. The 
SRSD was guided by the research completed in the first two objectives. The software 
requirements were used as the framework to guide the design and development process. 
Upon completion of the SRSD, the design phase could commence. 
1.5.3.1. Design of the Frontend 
Upon completion of the specification document, the user interface (UI) and user experience 
(UX) were designed. The UI was designed in conjunction with the UX, using Adobe XD to 
create low-fidelity mock-ups and wireframes, followed by interactive high-fidelity mock-ups. 
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Adobe XD was used as a wireframing tool, which provided a storyboard for the mobile app. 
The storyboard showed how the app flowed between screens, which represented the UX 
design. This concluded the design of the low-fidelity mock-up 
Once the UI had been designed and a storyboard had been created, an interactive high-fidelity 
mock-up was developed in order to test the UX and evaluate the UI. The high-fidelity mock-
up gave the mobile app and web app some functionality so that they could be tested by a 
group of potential users. This allowed technical malfunctions, like design errors and dead-end 
links, to be identified and the UI to be evaluated. The UI and UX were adapted during 
development of the prototype based on the effectiveness of the high-fidelity mock-up. 
1.5.3.2. Development of the Backend 
There are two main trends in mobile app development. The most common is the mobile-first 
approach where a single version of the app, aimed at a specific operating system is built, while 
other versions may be developed at a later stage (depending on the success of the first app) 
(Gropengießer & Sattler, 2014). The second trend is the application programming interface 
(API)-first approach (also known as backend as a service (BaaS)), where the backend is 
developed first so that apps can be built for various operating systems based on the same 
conditions (Gropengießer & Sattler, 2014). 
A BaaS provider allows the backend to be easily extended from the Android operating system 
to iOS or a web app (Firebase, 2019a). It facilitates app updates seamlessly, it offers on-
demand scalability options for improved performance and it secures data (Firebase, 2019a). 
Firebase is Google’s BaaS which offers cloud services such as user authentication, real-time 
database, storage, hosting, and so on (Li et al., 2018). Firebase works seamlessly with Android 
mobile apps (because Firebase and Android are both owned by Google) and connects easily 
with Android Studio, the integrated development environment (IDE) (Firebase, 2019a). The 
Firebase cloud system also provides encrypted data transmission (Firebase, 2019b, Li et al., 
2018). 
A BaaS was used for the development of the backend because it offered more advantages 
than the mobile-first approach as described above. Firebase was used as the BaaS provider 
because of its desirable features. The BaaS was used to store data, including log-in credentials 
and blood glucose readings. The BaaS then distributed this data to the patient’s app and the 
healthcare professional’s app. 
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1.5.3.3. Development of the Mobile Application for Patients 
The mobile app was developed as a native app on the Android operating system. A native 
mobile app was chosen instead of a web app due its unhindered access to device hardware 
which was required for the purpose of this project (Jobe, 2013). The Android operating system 
was chosen because it was the most popular operating system (Giachetti & Marchi, 2017).  
Android Studio was used to develop the app because it was Android’s official IDE and it used 
the Java programming language which was familiar to the developer. This meant that the 
mobile app would be developed as an Android native mobile app instead of a hybrid mobile 
app. Android Studio also had a dedicated emulator and featured easy integration with 
Firebase which suited the developer’s needs. 
1.5.3.4. Development of the Web Application for Healthcare Professionals 
The web app was developed using a combination of HyperText Markup Language (HTML), 
Cascading Style Sheets (CSS) and JavaScript, which are the standard coding languages for web 
development (Jobe, 2013). A web app was chosen for healthcare professionals because 
healthcare professionals would not require access to the hardware of the device. The fact 
that web apps could run through a browser on any device (Jobe, 2013) made it a convenient 
choice. 
Visual Studio Code, an IDE which supported HTML, CSS and JavaScript, included a 
comprehensive ecosystem of plugins which fully supported the needs of the software 
developer. It was thus used for the development of the web app. 
1.5.3.5. Development of the interface with the Glucose Meters 
The app was designed to interface with a Bluetooth-enabled glucose meter in order to avoid 
the accidental or purposeful error in entry that could occur during manual entry. 
The interface can be facilitated with a wireless connection. Many glucose meters can 
wirelessly transfer data via Bluetooth or can transfer data through a wired connection using 
serial communication. Bluetooth is chosen to transfer the data because all smart glucose 
meters support Bluetooth connectability, whereas only some support wired transfer of data. 
It is also less convenient to transfer data over a wired connection in comparison to a wireless 
connection due to the limitations that come with wired connections of any sort. 
Jason Leslie Collier University of Cape Town 12 January 2020 
10 
 
The Android platform includes support for the Bluetooth network stack, which allows a 
mobile phone to wirelessly exchange data with other Bluetooth devices. The software 
developer has access to an Accu-Chek Instant glucose meter, which is readily available and 
affordable. Thus, this is the glucose meter which is used to transfer data to the app. 
1.5.3.6. Testing of the Gestational Diabetes mHealth Platform 
The platform was tested at various stages throughout the design and development process. 
Usability tests occurred once the frontend had been designed. The high-fidelity mock-up of 
the frontend was tested in the Division of Biomedical Engineering at the University of Cape 
Town, using a set of tasks (to ensure that all requirements had been met) and a usability 
questionnaire. The outcomes of the testing were used to guide the changes that the mock-up 
needed before it went into the development phase. 
Once the platform had been developed, it underwent alpha tests consisting of black box 
testing. This was done by using students and staff, including engineers, dieticians, clinicians 
and other healthcare professionals, in the Biomedical Engineering Division at the University 
of Cape Town who carried out tasks that the typical user might perform. The goal was to 
identify issues which could be fixed once development on a beta version of the GD mHealth 
platform began. 
1.6. Structure of Thesis 
Chapter 2 fulfils the first objective, which is the assessment the current GD management 
practices in South Africa. Chapter 3 assesses the existing mHealth solutions for GD, which 
fulfils the second objective. The third objective is the design, development and testing of the 
GD mHealth platform, which will be discussed extensively in chapter 4. A general discussion 
to link the preceding chapters will take place in chapter 5. Finally, chapter 6 will conclude the 
thesis and will list the limitations and recommendations for future development. 
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2. Gestational Diabetes Management Practices in South 
Africa 
This chapter reviews the existing gestational diabetes (GD) management practices in South 
Africa in the form of a narrative review in order to accurately identify the problem and the 
needs required to solve the problem. The GD epidemiology, complications and management 
practices are discussed, followed by a comparison of diabetes management practices in the 
private at public healthcare sectors of South Africa. 
GD is defined by Buchanan, Xiang & Page (2012) as glucose intolerance with its onset or first 
recognition occurring during pregnancy. It is caused by a reduced pancreatic β-cell function, 
which does not produce sufficient insulin to meet the increased requirements of late 
pregnancy (Buchanan, Xiang & Page, 2012). This results in a high level of glucose in the blood, 
which is an identifying factor of diabetes (Diabetes UK, 2006). This, in turn, increases the risk 
of complications for both the mother and child before, during and after birth (Garnweidner-
Holme et al., 2015). These complications can include emergency caesarean sections, 
gestational hypertension, neonatal hypoglycaemia, macrosomia, premature births, large for 
gestational age infants and Neonatal Intensive Care Unit (NICU) admissions (Carral et al., 
2015, Given et al., 2015, Guo et al., 2018, Mackillop et al., 2018, Miremberg et al., 2018, 
Rasekaba et al., 2018). 
GD is increasing in prevalence along with the increase in prevalence of obesity in women of 
child bearing age (Kampmann et al., 2015). The risks posed to both the mother and child due 
to the mismanagement of the disease is a major cause for concern (Adams & Rheeder, 2017). 
Therefore, it is important to pay attention to diagnostic, treatment and management 
procedures relating to pregnant women at risk of developing GD. This is especially important 
in a South African setting, because South Africa is now regarded as one of the world’s most 
obese nations (Adams & Rheeder, 2017). 
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2.1. Epidemiology of Gestational Diabetes 
Mathevula (2013) estimates that there are well over 1.5 million diabetics of all types in South 
Africa. According to the most recently released statistics from Statistics South Africa, diabetes 
(5.5% mortality) has surpassed HIV/Aids (4.8% mortality) to be the second highest cause of 
death in South Africa (Statistics South Africa, 2016a). Diabetes is a preventable non-
communicable disease which can be treated, yet it is ranked closely behind the number one 
cause of death, Tuberculosis (6.5% mortality) (Statistics South Africa, 2016a). This is largely 
due to the inadequate management practices of those diagnosed with T1D, T2D or GD (Pillay, 
Lutge & Aldous, 2016, Rotchford & Rotchford, 2002). 
Hyperglycaemia during pregnancy complicates 16% of live births worldwide according to a 
2013 study (Kampmann et al., 2015). This percentage is likely to have increased since 2013 
and will continue to increase into the future in line with the global trends in diabetes and 
obesity (Kampmann et al., 2015). In a South Africa where there are approximately 1 million 
births per year (Statistics South Africa, 2016b), the high prevalence of GD can result in a large 
number of complications due to mismanagement, which can add more pressure to a 
healthcare system which is already struggling to cope (Nhlapo, 2015).  
Adams & Rheeder (2017) performed an observational study at a level 1 clinic in Johannesburg 
to determine the prevalence of GD in a South African population group. The results indicated 
that out of 554 patients studied, the prevalence of GD was 25.8% if the universal screening 
method and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) 
criteria were used (Adams & Rheeder, 2017). The high prevalence of the disease in South 
Africa highlights the need for better GD management practises. 
2.2. Gestational Diabetes Induced Complications 
Complications that arise as a result of GD can be detrimental to both the mother and the 
child. These complications can arise during pregnancy, at delivery and after birth as explained 
in the following paragraphs. 
Women with GD are more likely to have maternal complications like non-elective caesarean 
sections (19.5% of GD cases) than those without (13.5% of non-GD cases) (Buchanan, Xiang & 
Page, 2012, Kampmann et al., 2015).  According to Kampmann et al. (2015), there is a high 
risk for women with GD to develop gestational hypertension disorders (11.3% of GD cases). 
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This finding is confirmed by Adams & Rheeder (2017) and Kim (2010), who found the 
prevalence of gestational hypertension in women with GD to be 34.3% and 10.7% - 15% 
respectively. GD results in a higher risk of shoulder dystocia (Kim, 2010) and a stronger chance 
of delivering a baby with macrosomia (Adams & Rheeder, 2017) than normal pregnancies. 
Some studies have found that the risk of stillbirth is increased fourfold during labour if the 
mother has GD (Buchanan, Xiang & Page, 2012, Kampmann et al., 2015, Kim, 2010).  
Buchanan, Xiang & Page (2012) further investigated the perinatal complications in women 
with GD versus women without and found that for women with GD, premature births were 
3% more frequent (confirmed by Kim (2010)), the need for intensive neonatal care was 1.3% 
more frequent, neonatal hypoglycaemia was 0.8% more frequent (confirmed by Kim (2010)) 
and large for gestational age new-borns were 7.9% more frequent. 
After birth, women with a history of GD are at a greater risk of developing T2D (at least a 
sevenfold increase), while their children have a greater risk of being obese (twice more likely), 
developing the metabolic syndrome (four times more likely) and developing T2D early in their 
lives (six times more likely), according to Kampmann et al. (2015). GD also increases a 
woman’s risk of the metabolic syndrome and cardiovascular disease postpartum threefold 
(Kampmann et al., 2015). The risks point to the need for better diagnosis, monitoring and 
treatment of women with GD so that these risks can be avoided. 
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2.3. Gestational Diabetes Cycle of Care 
The GD cycle of care in South Africa is investigated in this section. Figure 2.1 depicts the GD 
cycle of care. The components of the cycle are discussed in the sections below. 
 
Figure 2.1: Gestational diabetes cycle of care 
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2.3.1. Risk Factors 
The GD cycle of care begins when women, who are 24-28 weeks pregnant, are screened using 
various risk factors (Nhlapo, 2015). There are many risk factors relating to GD, including 
maternal obesity, advanced maternal age, a family history of diabetes, a previous history of 
GD and belonging to certain ethnic groups (Garnweidner-Holme et al., 2015). Those who are 
at risk undergo an oral glucose tolerance test (OGTT) for diagnosis purposes (Nhlapo, 2015). 
2.3.2. Diagnosis 
The diagnosis of GD involves an OGTT, because Haemoglobin A1c (HbA1c) is inadequate as a 
diagnostic tool during pregnancy (Kampmann et al., 2015). However, screening procedures 
and diagnosis criteria in South Africa are disorderly (Adams & Rheeder, 2017). While current 
international opinion favours the universal screening of all pregnant women for GD using 
IADPSG criteria, SEMDSA recommends risk factor-based selective screening at 24 - 28 weeks’ 
gestation using the World Health Organisation (WHO) 1999 criteria (Nhlapo, 2015). According 
to Adams & Rheeder (2017), risk factor-based selective screening is the predominant practice 
in South Africa; however, each provincial health department in South Africa can decide 
independently which diagnostic criteria to use (National Institute for Health and Care 
Excellence (NICE), IADPSG or WHO 1999 criteria). The variations in diagnostic criteria result in 
many women with GD not receiving uniform treatment.  
2.3.3. Disease Management 
Once diagnosed, disease management becomes of key importance. It is recommended that 
women with GD manage their disease by controlling their blood glucose levels, and through 
lifestyle interventions, including nutritional therapy, meeting exercise goals and managing 
weight gain (depending on pre-pregnancy weight) (American Diabetes Association, 2018, 
Buchanan, Xiang & Page, 2012, Kim, 2010). In more extreme cases, GD can be managed by 
using pharmacotherapy (American Diabetes Association, 2018). 
The American Diabetes Association (2018) recommends fasting and postprandial monitoring 
of blood glucose to achieve metabolic control in pregnant women with diabetes. Their 
guidelines are shown in Table 2.1. Glucose self-monitoring by patients is shown to minimise 
the risk of perinatal complications (Buchanan, Xiang & Page, 2012). 
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Table 2.1: Blood glucose level guidelines for gestational diabetes 
Time Blood Glucose Level 
Pre-prandial 5.3 mmol/L 
1 hour postprandial 7.8 mmol/L 
2 hours postprandial 6.7 mmol/L 
 
During gestation, the diet should provide an adequate calorie intake to promote neonatal and 
maternal health, help achieve glycaemic goals and promote appropriate gestational weight 
gain (American Diabetes Association, 2018, Kim, 2010). Relatively little information from 
controlled trials exist to guide nutritional recommendations for GD (Buchanan, Xiang & Page, 
2012); however, it is known that reducing caloric intake for overweight women, limiting 
carbohydrate content to 35–40% of total calories and focusing on complex rather than simple 
carbohydrates can lower glucose levels more effectively than the standard diet for pregnant 
women (Buchanan, Xiang & Page, 2012). The second of these diet modifications has been 
shown to improve perinatal outcomes in comparison to higher carbohydrate diets (Buchanan, 
Xiang & Page, 2012). Low carbohydrate diets are associated with fewer macrosomic infants, 
fewer caesarean deliveries, and less pharmacotherapy; however, lower glycaemic rates are 
associated with high carbohydrate diets, but this may be because diets rich in complex 
carbohydrates and low glycaemic foods enable greater carbohydrate consumption (Kim, 
2010). 
Weight targets are particularly emphasised if glucose goals are not met (Kim, 2010). It has 
been shown that small reductions in weight can improve glycaemic control (Kim, 2010). Miao 
et al. (2017) assessed the association between gestational weight gain and pregnancy 
outcomes in women with GD and found that excessive gestational weight gain increased the 
incidence of caesarean section and macrosomia, while inadequate gestational weight gain 
reduced the incidence of large for gestational age babies when compared with adequate 
gestational weight gain. This shows the need for women with GD to manage their bodyweight 
to remain within target bodyweight ranges. 
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Physical activity may improve glucose tolerance by improving insulin sensitivity (Kim, 2010, 
Tobias et al., 2011). The general guideline for exercise duration is at least 30 minutes of 
exercise several days a week (Kim, 2010). Furthermore, Tobias et al. (2011) found that higher 
levels of physical activity before pregnancy or in early pregnancy are associated with a 
significantly lower risk of developing GD. 
If pharmacologic treatment is required to achieve glycaemic targets, insulin is the preferred 
medication for treating hyperglycaemia in GD as it does not cross the placenta to a 
measurable extent, in comparison to Metformin and glyburide, which may by harmful to the 
foetus (American Diabetes Association, 2018, Kim, 2010). Oral agents lack long term safety 
data and are not recommended (American Diabetes Association, 2018). 
Management of GD by healthcare professionals is currently performed through regular 
hospital attendance every 1 to 4 weeks, depending on the stage of gestation and the severity 
of hyperglycaemia (Mackillop et al., 2018). Women are encouraged to record their blood 
glucose levels at 3 to 4 times a day in a paper logbook to be discussed with a healthcare 
professional during an outpatient service (Garnweidner-Holme et al., 2015).  
2.3.4. Record Keeping 
In South Africa, medical records are generally paper-based, loosely written documents used 
to record relevant medical information and facts about a patient (Mostert-Phipps, Pottas & 
Korpela, 2012). Paper-based record keeping is associated with many problems, including the 
possible loss of data due to human error, records being damaged and logistical difficulties 
relating to the transfer of data between facilities (Neupane et al., 2014), which contribute to 
the ineffectiveness of GD management practices in South Africa. While some institutions in 
the private healthcare sector have made a transition to digital record keeping (Mostert-
Phipps, Pottas & Korpela, 2012), the majority of women with GD from both sectors are still 
tracking their blood glucose levels in paper-based logbooks (Nhlapo, 2015). Apart from the 
problems mentioned above, paper-based logbooks are also susceptible to accidental and 
purposeful errors in data capture (Mackillop et al., 2014). The issues with paper-based 
logbooks point to the need to manage diabetes digitally instead. 
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2.3.5. The Effect of the Public and Private Sectors on the Management of Gestational 
Diabetes 
The cycle of care for patients in South Africa differs between the private and public healthcare 
sectors. The large gap between the private and public healthcare sectors is largely due to the 
difference in funding for each (Young, 2016). The public sector is government funded and 
offered to all South Africans without charge, but incurs long waiting times, rushed 
appointments, the use of old facilities and equipment, poor disease control and poor 
prevention practices (Young, 2016). The private sector, on the other hand, has more funding 
available from consumers and medical aid companies, which results in a higher quality of care 
(Young, 2016). Adila Hassim (2007) found that R33.2 billion (39% of total national expenditure 
on health) was spent on the public sector in 2005 versus the R43 billion (61% of total national 
expenditure on health) spent on the private sector. In 2005, the public sector served 37.9 
million people which equates to R875.98 per capita expenditure (Adila Hassim, 2007). In 
contrast, the private sector served only 6.9 million people which equates to R6231.88 per 
capita expenditure (Adila Hassim, 2007). This inequality affects the diabetes management 
practices in each sector. 
The management of diabetes (T1D, T2D and GD) in South Africa presents certain problems, 
especially in low income areas. Over 70% of low income South Africans live in rural areas 
where healthcare accessibility is limited (Wouters et al., 2009). Poor diabetic control in the 
South African public sector is caused by the lack of regular blood glucose monitoring by 
healthcare professionals and the lack of action taken when blood glucose levels are not up to 
standard (Rotchford & Rotchford, 2002). Also contributing to poor diabetic control in South 
Africa is the fact that the adherence to treatment of chronic diseases is less than 66% 
(Mathevula, 2013, Wouters et al., 2009). Levitt (2008) says that the problem with diabetes 
management in South Africa is as a result of a lack of resources allocated to healthcare in low 
income economies, where the majority of the limited resources are allocated to acute care 
instead of chronic care. Levitt (2008) also cites the lack of functioning equipment for routine 
monitoring as a contributing factor to the poor management of diabetes as well as the lack of 
education programmes in place for patients and staff. These problems have resulted in 62% 
of diabetics in South Africa going undiagnosed (Pillay, Lutge & Aldous, 2016). These studies 
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show the need for a better method of managing diabetics in low income areas of South Africa 
which may benefit from the use of mHealth, according to Wouters et al. (2009). 
Although the private healthcare sector in South Africa offers a greater quality of care than the 
public healthcare sector, diabetes management practices in the private sector are still 
suboptimal when assessed according to HbA1c levels (Amod, Riback & Schoeman, 2012). 
According to data from the Council for Medical Schemes, about 3.3% of beneficiaries were 
treated for diabetes in South Africa in 2016 (Govuzela, Thsehla & de Villiers, 2018). Over 70% 
of these patients in the private sector had HbA1c values greater than 7% (the target 
recommended by the SEMDSA guidelines at the time of the survey) versus 84.3% of patients 
in the  public sector (Rotchford & Rotchford, 2002). The most common reason indicated by 
doctors for patients in the private sector not reaching their HbA1c goals is due to a lack of 
compliance with lifestyle recommendations (29.5%) and a lack of efficacy for their intended 
antidiabetic treatment (23.5%) (Amod, Riback & Schoeman, 2012). 
Chapter 3 builds on the research in this chapter by reviewing the existing mHealth solutions 
for GD. This is done to assess the effectiveness of mHealth for GD management and determine 
whether mHealth may benefit the current GD management practices in South Africa. 
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3. Existing mHealth Solutions for Gestational Diabetes 
The objective of this chapter is to perform a comprehensive review of the literature relating 
to existing mHealth solutions for gestational diabetes (GD), including the benefits and 
challenges of mHealth, the effectiveness of mHealth used for GD and the important features 
and functions of existing GD mHealth solutions. The analysis broadly follows the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework (Moher et 
al., 2009).  
3.1. Introduction 
Mobile health (mHealth) is defined by Kahn, Yang & Kahn (2010) as the use of portable 
electronic devices for data communication via the internet to provide health information. The 
global penetration of smartphones is 48%, according to Kahn, Yang & Kahn (2010), which is 
one of the reasons that mobile devices are being used in the healthcare industry. 
The nature of chronic diseases like diabetes requires a well-integrated and resource-rich 
healthcare system, which is why chronically ill patients are often poorly managed in low and 
middle income countries (LMIC) (Bloomfield et al., 2014). The need for those with chronic 
illnesses, like diabetes, to manage their own treatment means that public health systems 
must utilise mobile technologies in order to equip patients to do so (Kahn, Yang & Kahn, 
2010). During the 2011 United Nations High Level Meeting on Non-Communicable Diseases, 
mHealth was highlighted as a key strategy to combat chronic diseases in LMIC (Bloomfield et 
al., 2014). Kahn, Yang & Kahn (2010) emphasised that the potential of mHealth in LMIC is as 
a result of the prominent use of smartphones in these countries. In South Africa (which has 
universal mobile phone penetration), 40% of all mobile phones are smartphones and this 
number is said to increase drastically in the near future (Barron et al., 2018). Bloomfield et al. 
(2014), who found that there are more mobile phone subscribers in south Saharan Africa than 
in the United States or European Union, agrees that there is a role for mHealth in Africa. 
The benefits of using mHealth to manage diabetes and other chronic diseases is well 
documented. The main benefits of mHealth are the ability to graphically view trends (Årsand 
et al., 2010), the ability to collect data in real-time (Barron et al., 2018) and the potential for 
remote diagnosis, monitoring and treatment (Bloomfield et al., 2014, Kahn, Yang & Kahn, 
2010, Veazie et al., 2018). The disease education abilities of mHealth (Bloomfield et al., 2014, 
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El-Gayar et al., 2013, Kahn, Yang & Kahn, 2010) and the improved self-management due to 
mHealth (Cafazzo et al., 2012, Kahn, Yang & Kahn, 2010) are associated with better health 
outcomes (Pais et al., 2017). The ability to connect to external devices for automatic data 
entry (Cafazzo et al., 2012, El-Gayar et al., 2013) and the ability to communicate directly with 
healthcare professionals (El-Gayar et al., 2013) regarding the recorded data are seen as major 
advantages of mHealth. There is a possibility of integrating mHealth platforms with a personal 
health record (PHR) (El-Gayar et al., 2013) or managing multiple health conditions through 
one health and wellness mobile app (Pais et al., 2017) which may be advantageous to the 
management of one’s health. Social networking, which can be supported by mHealth, acts as 
a source of motivation and information and is thus seen as a major advantage of using 
mHealth (Cafazzo et al., 2012, Kahn, Yang & Kahn, 2010) 
There are many challenges relating to mHealth, however. Bloomfield et al. (2014) state that 
while there are numerous examples of mHealth being used for chronic diseases, there is 
insufficient evidence to support the effectiveness of mHealth. Other disadvantages 
associated with mHealth include the transfer of incorrect information through error which 
may create alarm,  the misinterpretation or misunderstanding of presented information due 
to inadequate literacy or hasty reading, the loss of human interaction for teaching and the 
possible loss of confidentiality (Kahn, Yang & Kahn, 2010). Wouters et al. (2009) state that 
healthcare professionals and patients in developing countries like South Africa may struggle 
to use new technologies or may see mHealth platforms as an extra burden in an already time-
constrained, administration-intensive environment (Barron et al., 2018). Patients might 
regard mHealth as a replacement for a face-to-face visit with a health worker as opposed to 
being supplementary to face-to-face visits (Wouters et al., 2009). Network charges are also 
costly, especially for those in rural areas who arguably need the help of mHealth services 
most. This, combined with the fact that there may be parts of rural areas where network 
coverage is poor, may hinder the effectiveness of mHealth platforms (Wouters et al., 2009). 
Another concern raised in literature has to do with security and privacy related problems in 
mHealth which arise due to the unsecured transfer of private data or theft of a device which 
may contain private data (El-Gayar et al., 2013). Skar et al. (2018) pointed out that that the 
patients’ trust in the subjective and intuitive knowledge of healthcare professionals will 
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decrease with the use of mHealth and that the responsibility for the patient to self-manage 
his or her own health may add further to the burden of the disease. 
3.2. Methods 
The methods detailed here describe the process followed in order to evaluate the 
effectiveness of mHealth when applied to GD as well as the important GD mHealth features 
and functions. The methods follow a systematic review process. 
3.2.1. Research Question 
This study focuses on the research question: “Will mHealth act as a more effective 
management solution for women with GD when compared with the existing GD management 
practices?” 
Table 3.1 shows the PICO research question, which included the population (P) group of 
women with GD, the intervention (I), which was the use of mHealth, the comparison (C) group 
of women with GD who received the standard care and the outcome (O), which was the 
effectiveness of the management practices. 
3.2.1.1. Population 
The population included women with GD. However, pregnant women who had previously 
been diagnosed with T1D or T2D were also included, because they followed a similar cycle of 
care as women who were diagnosed with GD (over the last 12 to 16 weeks of gestation) 
according to Buchanan, Xiang & Page (2012).  
3.2.1.2. Intervention and Comparison 
The intervention of mHealth included all forms of electronic devices which transferred data 
via an internet connection to provide health information. The comparison was with the 
existing GD management practices (depicted in Figure 2.1). 
3.2.1.3. Outcome 
The primary outcome of this research was to gauge the effectiveness of the intervention by 
comparing intervention groups and comparison groups, measuring the: 
 biological outcomes (blood glucose levels and Haemoglobin A1c (HbA1c) levels),  
 maternal outcomes (vaginal delivery rates, caesarean section rates, gestational ages 
at delivery and gestational hypertension rates),  
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 perinatal outcomes (birth weights, neonatal hypoglycaemia rates, macrosomia rates, 
Neonatal Intensive Care Unit (NICU) admission rates and premature birth rates),  
 behavioural outcomes (patient compliance levels),  
 economic outcomes (frequency of outpatient services and healthcare related costs), 
and  
 cognitive outcomes (patient and healthcare professional satisfaction levels).  
The secondary outcomes from this review determined what the existing mHealth solutions 
(and their features) for GD were and what the related benefits and challenges were. The 
outcomes were displayed on forest plots and analysed for statistical significance and level of 
heterogeneity. 
Table 3.1: PICO research question 
PICO 
Will mHealth act as a more effective management solution for women 
with GD when compared with the existing GD management practices? 
Population Women with GD 
Intervention mHealth 
Comparison Existing GD management practices 
Outcome Effective management 
 
3.2.2. Eligibility Criteria 
Table 3.2 shows the inclusion and exclusion criteria applied during the search of each 
database. Journal articles were included due to the review process they underwent, ensuring 
good quality information. The January 2014 and December 2018 date restrictions excluded 
any mHealth interventions prior to this 5-year period, as these were deemed irrelevant as a 
result of fast progressing mHealth related technologies. Only English articles were included. 
All articles with population groups including animals or males were excluded because they 
did not form part of the research question.  
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Table 3.2: Inclusion and exclusion criteria 
Article type Peer-reviewed articles 
Article publication date 2014 – 2018 
Article language English 
Population species Humans 
Population gender Female 
 
3.2.3. Search Strategy 
Table 3.3 shows the search strategy. It includes the keywords used to search the databases 
for relevant articles. 
The search was performed from the 19th to the 23rd of November, 2018, with the help of a 
professional librarian, using the following databases: Academic Search Premier, CINAHL, 
Computers and Applied Sciences Complete, EBSCOHost, EI Compendex, Health Source: 
Nursing/Academic Edition, IEEE Electronic Library, Pubmed, PsycINFO, Scopus, Technology 
Research Database and Web of Science.  
Table 3.3: Search strategy 
Population: GD 
#1 MeSH terms diabetes, gestational 
#2 Free text (gestational OR gestation OR pregnancy-induced OR 
(pregnancy induced)) AND (diabetes OR diabetic) 
#3 (#1 OR #2) (population) 
Intervention: mHealth 
#4 MeSH terms telemedicine OR computers, handheld OR medical 
informatics applications OR mobile applications 
#5 Free text Android OR blog OR cell phones OR cellular phones 
OR computer OR digital health OR digital health 
interventions OR e-counselling OR eHealth OR e-
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health OR Facebook OR handheld computers OR ICT 
OR information communications technology OR iPad 
OR iPhone OR internet-based OR messaging OR 
mHealth OR m-health OR mms OR mobile apps OR 
mobile applications OR mobile-based OR mobile 
devices OR mobile health OR mobile phones OR 
mobile technology OR online chat OR online social 
network OR phone OR podcasts OR portable 
electronic applications OR SMS OR smartphones OR 
smart phone OR social media OR telecommunication 
in medicine OR telecare OR telehealth OR telephone-
based OR telemedicine OR text messaging OR text 
messages OR tweet OR twitter OR WhatsApp OR 
WeChat OR web-based OR web site OR website OR 
web app 
#6 #4 OR #5 (intervention) 
#7 #3 AND #6 (search without filters) 
#8 Publication dates: 2014 - 2018 
#9 #7 AND #8 (final search) 
 
3.2.4. Study selection 
The author screened all the articles based on their titles and abstracts to identify potentially 
significant articles from the original search. The full texts of the remaining articles were then 
evaluated by the author. Ineligible articles were excluded based on the eligibility criteria. 
The title and abstract screening and full text screening criteria used were as follows: 
 The population group in the article must have been about women who have GD. 
 The intervention in the article must have been mHealth related. 
 One of the primary outcomes investigated in the article must have been blood 
glucose levels. 
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3.2.5. Quality Assessment and Data Extraction 
Each of the randomised control trials were scored for the risk of bias using the Cochrane 
Collaboration Risk of Bias Tool. Data relating to the primary and secondary outcomes was 
extracted by the author and stored using Review Manager (RevMan Version 5.3). The 
extracted data included blood glucose levels, HbA1c levels, vaginal delivery rates, caesarean 
section rates, gestational ages, birthweights, hypoglycaemia rates, NICU admission rates, 
premature birth rates, hypertension rates, patient compliance rates and healthcare costs. 
3.2.6. Statistical Analysis 
Review Manager (RevMan Version 5.3) was used for the meta-analysis. For outcomes of the 
dichotomous data type, the Mantel-Haenszel statistical method was used with the risk ratio 
effect measure. For outcomes of the continuous data type, the inverse variance statistical 
method was used with the mean difference effect measure. Results were presented with a 
95% confidence interval (CI). 
A large amount of heterogeneity was expected because of the substantial variance in the 
included studies in terms of standards of care and research methodologies utilised. Therefore, 
the random effects analysis model was applied and the I2 characteristic was reported. 
Heterogeneity was estimated using I2, with an I2 value greater than 50% representing 
substantial heterogeneity (Higgins et al., 2003). The results were seen as significant if P was 
less than 0.05 (Higgins et al., 2003). The pooled data was displayed in a forest plot, but only if 
there were more than three studies with relevant data. 
3.3. Results 
The search results from the systematic review and the statistical results from the meta-
analysis are detailed in the sections below.  
3.3.1. Study Selection 
The search results are displayed in Table 3.4 and the search process used is depicted in Figure 
3.1 as a PRISMA flow diagram (PRISMA, 2019).  
Endnote was used as a reference management tool. Once the search was complete, all 1109 
references were saved in Endnote, which was used to automatically remove duplicates, 
leaving 875 unique references. Once the title and abstract of the articles were screened as 
per the eligibility criteria, 49 references remained. The screening of the full text of each article 
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left 26 applicable articles. Articles were excluded for the following reasons: the article was a 
duplicate, the full text was inaccessible, the intervention was incorrect, the population was 
incorrect, or no results were given.  
Table 3.4: Search results 
Database References References 
after duplicates 
References 









180 135 8 3 




13 10 2 1 




42 5 0 0 
IEEE Electronic 
Library 
0 0 0 0 
PsycINFO 14 6 1 0 
Pubmed 298 297 24 19 
Scopus 72 33 2 0 
Technology 
Research Database 
41 27 0 0 
Web of Science 299 292 6 0 
Total 1109 875 50 26 






Figure 3.1: PRISMA flow diagram - generated using PRISMA Flow Diagram Generator (PRISMA, 2019) 
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3.3.2. Study Characteristics 
The included studies can be split into different categories, including qualitative studies, 
quantitative studies, development and evaluation studies, systematic reviews and 
miscellaneous studies. Table 3.5 displays the studies arranged into their respective categories. 
Table 3.6 shows the characteristics of each qualitative study included in the meta-analysis. 
The eight quantitative studies were focused on for the meta-analysis. The qualitative studies 
and development studies were primarily used to identify the main features and functions of 
existing mHealth solutions for GD. The systematic reviews were used as a source of related 
work to which results could be compared. 
The eight quantitative studies included a total of 791 participants, 399 in the intervention 
group and 391 in the control group. The studies were conducted across nine countries, 
including the United States (Bartholomew et al. (2015)), Switzerland (Bromuri et al., 2016), 
Spain (Carral et al., 2015), Northern Ireland (Given et al., 2015), Republic of Ireland (Given et 
al., 2015), China (Guo et al., 2018), United Kingdom (Mackillop et al., 2018), Israel (Miremberg 
et al., 2018) and Australia (Rasekaba et al., 2018). All the individual studies were relatively 
small in size, ranging from 24 to 203 participants (a population size of around 1000 is required 
according to Ming et al. (2016)). All the studies were peer-reviewed articles and all of them 
were supported by grants. Seven of the studies used randomised controlled trial (RCT) designs 
and one used a controlled clinical trial (CCT) design (Carral et al., 2015). 




Holme, L. et al. 
(2018)
• Hirst et al. 
(2015)
• Nicholson et al. 
(2016)
• Pais et al. (2017)
• Skar et al. (2018)
Quantitative
• Bartholomew et 
al. (2015)
• Bromuri et al. 
(2016)
• Carral et al. 
(2015)
• Given et al. 
(2015)
• Guo et al. (2018)
• Mackillop, L. et 
al. (2018)
•Miremberg et al. 
(2018)




• Jo & Park (2016)








• Lau et al. (2016)
• Ming et al. 
(2016)




•Bashshur et al. 
(2015)
•Chilelli, Dalfrà & 
Lapolla (2014)
•Hirst et al. (2016)
•Pustozerov et al. 
(2018)
•Rigla et al. (2018)
•Wickramasinghe, 
Teoh & Mercieca 
(2015)




Table 3.6: Study characteristics 
HP = healthcare professional, I = intervention group, C = control group  


































































































































Bartholomew et al. (2015) 
74 
(40:34) 
App logbook with automatic data entry 
Data reviewed via website by HP 
              
Bromuri et al. (2016) 
24 
(12:12) 
App logbook with manual data entry 
Data reviewed via website by HP 
              
Carral et al. (2015) 
104 
(40:64) 
Website logbook with manual data entry 
Data reviewed via website by HP 
              
Given et al. (2015) 
47 
(21:26) 
Telemedicine hub with automatic data entry 
Data available on website logbook for patients 
Data reviewed via website by HP 
              
Guo et al. (2018) 
124 
(64:60) 
App logbook with automatic or manual data entry 
Data reviewed via app by HP 
              
Mackillop et al. (2018) 
203 
(101:102) 
App logbook with automatic data entry 
Data reviewed via app by HP 
              
Miremberg et al. (2018) 
120 
(60:60) 
App logbook with manual data entry 
Data reviewed via exported results by HP 
              
Rasekaba et al. (2018) 
95 
(61:34) 
Website logbook with manual data entry 
Data reviewed via website by HP 
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3.3.3. Study Quality 
The study quality is assessed by evaluating the risk of bias. Figure 3.2 depicts the risk of bias 
of the eight quantitative studies and Figure 3.3 depicts the summary of the risk of bias.  
Included studies displayed potential sources of methodological bias. A total of six studies out 
of the eight adequately randomised the sequence generation. There were two studies with 
adequate sequence concealment. Due to the nature of the intervention, blinding of 
participants and personnel was not possible in any of the studies. None of the studies 
addressed the blinding of outcome assessments and were all marked with an unclear risk. All 
the studies had an unclear risk of selective reporting. 
 
Figure 3.2: Risk of bias graph 
 
Figure 3.3: Risk of bias summary 
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3.3.4. Biological Outcomes 
The biological results are displayed as forest plots. Figure 3.4 depicts the forest plot of the 
total blood glucose levels and Figure 3.5 depicts a forest plot of the HbA1c levels. 
There were three studies which assessed the blood glucose levels (Figure 3.4) as an outcome 
(Bartholomew et al., 2015, Bromuri et al., 2016, Miremberg et al., 2018). The meta-analysis 
revealed that the intervention reduced overall (pre-prandial and postprandial combined) 
blood glucose levels with a mean difference of -0.38 mmol/L (95% CI -0.52 mmol/L to -0.23 
mmol/L). The results were homogeneous (I2 = 0%) and were statistically significant (P < 
0.00001).  
 
Figure 3.4: Forest plot of blood glucose levels (total) 
The HbA1c levels (Figure 3.5) were also reduced by the intervention, as assessed by four 
studies (Carral et al., 2015, Given et al., 2015, Guo et al., 2018, Mackillop et al., 2014), with a 
mean difference of -0.13% (95% CI -0.47% to 0.22%). The results were substantially 
heterogeneous (I2 = 98%) and not statistically significant (P = 0.48).  
 
Figure 3.5: Forest plot of HbA1c levels 
Bartholomew et al. (2015) and Bromuri et al. (2016) assessed the effects of the intervention 
on pre-prandial and postprandial blood glucose levels. Both found that the mean pre-prandial 
and postprandial blood glucose levels were less for the women using mHealth interventions 
than for women receiving regular care. The rate of off target measurements was found to be 
lower in the intervention group than in the control group for both pre-prandial and 
postprandial measurements (Guo et al., 2018, Miremberg et al., 2018). These findings were 
supported by Mackillop et al. (2018) who reported that blood glucose declined faster in the 
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intervention group compared to the control group by a statistically significant margin. 
Mackillop et al. (2018) also found that, although HbA1c levels increased for both groups from 
recruitment to delivery, the intervention group’s HbA1c levels increased at a lesser rate than 
the control group’s HbA1c; however, this was not statistically significant. 
3.3.5. Maternal Outcomes 
The following forest plots are illustrated as per the maternal outcomes: Figure 3.6: Forest plot 
of normal vaginal deliveries, Figure 3.7: Forest plot of caesarean sections, Figure 3.8: Forest 
plot of emergency caesarean sections, Figure 3.9: Forest plot of gestational ages at delivery 
and Figure 3.10: Forest plot of gestational hypertension or pre-eclampsia. 
Mackillop et al. (2018), Miremberg et al. (2018) and Guo et al. (2018) found that there was a 
higher probability of vaginal deliveries (Figure 3.6) in the intervention group than in the 
control group (shown by a risk ratio of 1.18). The results were homogeneous (I2 = 0%) and 
statistically significant (P = 0.02).  
 
Figure 3.6: Forest plot of normal vaginal deliveries 
There were six studies (Carral et al., 2015, Given et al., 2015, Guo et al., 2018, Mackillop et 
al., 2018, Miremberg et al., 2018, Rasekaba et al., 2018) which reported on the number of 
caesarean sections (Figure 3.7). The results showed that women in the intervention groups 
were less likely to have a caesarean section (shown by a risk ratio of 0.81). The results were 
of an acceptable level of heterogeneity (I2 = 46%) but were not statistically significant (P = 
0.17).  




Figure 3.7: Forest plot of caesarean sections 
Of the above six studies, three (Mackillop et al., 2018, Miremberg et al., 2018, Rasekaba et 
al., 2018) reported on the number of emergency caesarean sections (Figure 3.8). Although 
the results were substantially heterogeneous (I2 = 66%) and not statistically significant, they 
found that women in the intervention group were less likely to have an emergency caesarean 
section than women in the control group (shown by a risk ratio of 0.23).  
 
Figure 3.8: Forest plot of emergency caesarean sections 
The gestational ages at delivery were reported on by six studies (Carral et al., 2015, Given et 
al., 2015, Guo et al., 2018, Mackillop et al., 2018, Miremberg et al., 2018, Rasekaba et al., 
2018). Figure 3.9 shows that there was practically no difference in gestational ages at delivery 
between the groups (shown by a risk ratio of 0.01). The data was substantially heterogeneous 
(I2 = 78%) and was not statistically significant (P = 0.05).  
 
Figure 3.9: Forest plot of gestational ages at delivery 
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There were four studies (Carral et al., 2015, Given et al., 2015, Mackillop et al., 2018, 
Miremberg et al., 2018) which assessed the number of gestational hypertension cases (Figure 
3.10). The studies found that women in the intervention group were less likely be diagnosed 
with gestational hypertension than women in the control group (shown by a risk ratio of 0.67). 
The results were homogeneous (I2 = 0%) but were not statistically significant (P = 0.42).  
 
Figure 3.10: Forest plot of gestational hypertension or pre-eclampsia 
Miremberg et al. (2018) and Carral et al. (2015) also investigated the number of women who 
had to undergo insulin treatment during pregnancy and found that women in the intervention 
group were significantly less likely to be on insulin during pregnancy than women in the 
control group. 
3.3.6. Perinatal outcomes 
The following forest plots are illustrated as per the maternal outcomes: Figure 3.11: Forest 
plot of birthweights, Figure 3.12: Forest plot of neonatal hypoglycaemia cases, Figure 3.13: 
Forest plot of macrosomia cases, Figure 3.14: Forest plot of NICU admissions and Figure 3.15: 
Forest plot of premature births. 
Birthweights (Figure 3.11) in the control and intervention groups were assessed by five 
studies (Carral et al., 2015, Given et al., 2015, Mackillop et al., 2018, Miremberg et al., 2018, 
Rasekaba et al., 2018). The results showed that the mean birthweight of new-borns from the 
intervention group was 16.94 g (95% CI -105.74 g to 139.62 g) higher than that of new-borns 
from the control group. The results were substantially heterogeneous (I2 = 52%) and not 
statistically significant (P = 0.79).  




Figure 3.11: Forest plot of birthweights 
The meta-analysis of the neonatal hypoglycaemia cases (Figure 3.12) showed that it was less 
likely for new-borns from the intervention group to be diagnosed with hypoglycaemia than 
new-borns from the control group (shown by a risk ratio of 0.67), as shown by four studies 
(Carral et al., 2015, Given et al., 2015, Guo et al., 2018, Mackillop et al., 2018). The results 
were homogeneous (I2 = 0%) and were statistically significant (P = 0.02).  
 
Figure 3.12: Forest plot of neonatal hypoglycaemia cases 
There were three studies (Given et al., 2015, Guo et al., 2018, Rasekaba et al., 2018) which 
assessed the number of macrosomia cases (Figure 3.13). The studies found that new-borns 
from the intervention group were more likely have macrosomia than new-borns from the 
control group (shown by a risk ratio of 1.44). The results were of an acceptable heterogeneity 
(I2 = 40%) but were not statistically significant (P = 0.54).  
 
Figure 3.13: Forest plot of macrosomia cases 
NICU admissions (Figure 3.14) in the control and intervention groups were assessed by four 
studies (Given et al., 2015, Mackillop et al., 2018, Miremberg et al., 2018, Rasekaba et al., 
Jason Leslie Collier University of Cape Town 12 January 2020 
37 
 
2018). The results showed that there were practically no differences in the likelihood of new-
borns being admitted to the NICU between the intervention and control groups (shown by a 
risk ratio of 1.01). The results were of an acceptable heterogeneity (I2 = 47%) but were not 
statistically significant (P = 0.98).  
 
Figure 3.14: Forest plot of NICU admissions 
The meta-analysis of the premature births (Figure 3.15) showed that it was less likely for new-
borns from the intervention group to be born prematurely than new-borns from the control 
group (shown by a risk ratio of 0.50), as shown by three studies (Carral et al., 2015, Given et 
al., 2015, Mackillop et al., 2018). The results were homogeneous (I2 = 0%) but were not 
statistically significant (P = 0.08).  
 
Figure 3.15: Forest plot of premature births 
Both Carral et al. (2015) and Mackillop et al. (2018) found that women in the intervention 
group were more likely to produce large for gestational weight new-borns than women in the 
control group; however, these findings were not statistically significant. 
3.3.7. Cognitive Outcomes 
There were three studies which assessed patient compliance (actual blood glucose 
measurements divided by instructed measurements) as an outcome (Bartholomew et al., 
2015, Guo et al., 2018, Miremberg et al., 2018). The meta-analysis revealed that women in 
the intervention group were 10.9% (95% CI -0.27% to 22.06%) more compliant than women 
in the control group. The results were substantially heterogeneous (I2 = 99%) and were not 
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statistically significant (P = 0.06). Mackillop et al. (2018) and Bromuri et al. (2016) supported 
these findings; however, their measures of compliance were different to the three studies 
included in the meta-analysis.  
Figure 3.16 shows a forest plot of the patient compliance percentages. 
 
Figure 3.16: Forest plot of patient compliance 
3.3.8. Economic Outcomes 
Mackillop et al. (2018) assessed the healthcare costs for women with GD. It was found that 
women in the intervention group paid a mean cost difference of –£1044 (95% CI –£2186 to 
£99) less than women in the control group. However, the results were not statistically 
significant. Rasekaba et al. (2018) found that the intervention had no impact on service 
provider costs. 
The frequency of outpatient services was reduced by the intervention, as assessed by three 
studies (Guo et al., 2018, Mackillop et al., 2018, Rasekaba et al., 2018), with a mean difference 
of -1.35 (95% CI -3.36 to 0.65). The results were substantially heterogeneous (I2 = 96%) and 
were not statistically significant (P = 0.19). Carral et al. (2015) supported these findings but 
reported the results in a different manner to the studies included in the meta-analysis. 
Figure 3.17 shows a forest plot of the frequency of outpatient services. 
 
Figure 3.17: Forest plot of the frequency of outpatient services 
3.3.9. Behavioural Outcomes 
Garnweidner-Holme et al. (2018) investigated how health care professionals perceived the 
provision of mHealth to women with GD and found that they saw it as an appropriate tool for 
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the management of GD. Hirst et al. (2015) assessed the user satisfaction of a GD mHealth 
platform using a structured questionnaire assessing (1) general satisfaction, (2) equipment 
issues, and (3) relationship with the diabetes care team and found that GD mHealth was 
acceptable and convenient for a large proportion of women.  
The benefits reported by the various studies included: 
 the convenience of recording blood glucose levels digitally as opposed to using paper 
logbooks (Garnweidner-Holme et al., 2018, Pais et al., 2017, Skar et al., 2018) and 
the convenience of viewing the results graphically (Skar et al., 2018), 
 the smaller chance of error in digital data entry (Mackillop et al., 2018), 
 the alerts and reminders provided by the mHealth platform (Anderson, 2017), 
 the two-way communication with healthcare professionals who can provide 
feedback (Anderson, 2017), 
 the ease of access to GD related information for patients (Garnweidner-Holme et al., 
2018, Skar et al., 2018), 
 the transport and outpatient service time saved for patients (Hirst et al., 2015),  
 the real-time analysis of blood glucose data by healthcare professionals (Mackillop et 
al., 2018),  
 the ease of access to patient data for healthcare professionals (Pais et al., 2017), and 
 time and cost effectiveness of remote monitoring for healthcare professionals (Pais 
et al., 2017). 
The challenges reported by the various studies included: 
 the technical difficulties, especially relating to the automatic transfer of blood 
glucose levels, which created a barrier for use for patients (Garnweidner-Holme et 
al., 2018, Skar et al., 2018), 
 the lack of interoperability between mHealth apps and glucose meter devices (Skar 
et al., 2018),  
 ensuring that mHealth provided GD information matched with healthcare provided 
information (Garnweidner-Holme et al., 2018, Skar et al., 2018), 
 the general nature of the GD information (Skar et al., 2018),  
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 providing culturally inclusive nutritional advice to patients (Garnweidner-Holme et 
al., 2018), 
 the possible loss of privacy of patient data (Given et al., 2015), and 
 convincing healthcare professionals to adopt the new technology (Skar et al., 2018). 
3.3.10. Features and Functions of a GD mHealth Platform 
The reviewed literature found the following GD mHealth platform features and functions to 
be prominent. The GD mHealth platform should: 
 record initial assessment data (Bromuri et al., 2016, Jo & Park, 2016), 
 automatically upload blood glucose data (Garnweidner-Holme et al., 2018, Guo et al., 
2018), 
 record the patient’s food intake (Garnweidner-Holme et al., 2015, Guo et al., 2018, Jo 
& Park, 2016, Miremberg et al., 2018, Rasekaba et al., 2018), physical activity duration 
(Garnweidner-Holme et al., 2015, Guo et al., 2018, Jo & Park, 2016, Miremberg et al., 
2018), body weight (Bromuri et al., 2016, Given et al., 2015, Jo & Park, 2016, 
Miremberg et al., 2018), blood pressure (Bromuri et al., 2016, Given et al., 2015, 
Miremberg et al., 2018) and symptoms (Bromuri et al., 2016, Rasekaba et al., 2018) in 
addition to blood glucose, 
 allow the patient to label blood glucose readings with pre-prandial or postprandial 
tags (Bromuri et al., 2016, Carral et al., 2015, Guo et al., 2018, Mackillop et al., 2014) 
and allow comments to be added if necessary (Mackillop et al., 2014) 
 record the medication that is taken (Bromuri et al., 2016, Carral et al., 2015, Jo & Park, 
2016, Mackillop et al., 2014, Miremberg et al., 2018, Rasekaba et al., 2018) 
 display all recorded data both graphically (Bromuri et al., 2016, Jo & Park, 2016, 
Mackillop et al., 2014, Miremberg et al., 2018) and numerically (Bromuri et al., 2016, 
Mackillop et al., 2014), with colour-coded thresholds (Mackillop et al., 2014), for a 
selectable period, 
 provide reminders and alerts to patients (Guo et al., 2018, Jo & Park, 2016), 
 allow healthcare professionals to provide feedback and educational information 
(Bartholomew et al., 2015, Garnweidner-Holme et al., 2015, Guo et al., 2018, Jo & 
Park, 2016, Mackillop et al., 2018), 
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 allow two-way communication between patients and healthcare professionals to 
occur (Carral et al., 2015, Guo et al., 2018, Mackillop et al., 2014), and 
 transmit data to healthcare professionals for remote monitoring (Bartholomew et al., 
2015, Bromuri et al., 2016, Carral et al., 2015, Given et al., 2015, Guo et al., 2018, 
Mackillop et al., 2014). 
The healthcare professional’s web app should allow healthcare professionals to: 
 view all linked patients with a summary (Bromuri et al., 2016, Mackillop et al., 2014), 
 display and modify personal information and clinical information (Bromuri et al., 
2016, Mackillop et al., 2014), 
 display remotely recorded data graphically and in tabular form for a selectable 
period (Mackillop et al., 2014), 
 add a note next to noteworthy data (Bromuri et al., 2016, Mackillop et al., 2014), 
 be alerted to patients who are not meeting clinical goals (Bromuri et al., 2016, 
Mackillop et al., 2014, Mackillop et al., 2018), 
 view and schedule consultations (Bromuri et al., 2016), 
 read and write messages to and from patients (Carral et al., 2015, Mackillop et al., 
2014), and 
 determine when the patient will require more strips with a strip counter (Mackillop 
et al., 2014). 
Initial assessment data should record: 
 pre-pregnancy bodyweight (Bromuri et al., 2016, Jo & Park, 2016), 
 height (Jo & Park, 2016), 
 due date (Bromuri et al., 2016, Jo & Park, 2016), 
 history of diabetes (Bromuri et al., 2016, Jo & Park, 2016), 
 residential address (Bromuri et al., 2016), and 
 contact details (Bromuri et al., 2016). 
3.4. Discussion 
The eight studies included in the meta-analysis were small in population size (Ming et al., 
2016), assessed different forms of mHealth technologies and were deemed to contain a 
moderate source of potential bias, so it was not possible to draw concrete conclusions from 
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all of the results. It was shown that mHealth offered several advantages in terms of biological, 
maternal, perinatal, cognitive and economic outcomes. Many of the outcomes which 
favoured mHealth were based on substantially heterogeneous results (I2 > 50%) and non-
statistically significant margins (P > 0.05). It was reassuring that the evidence clearly showed 
that mHealth was not associated with harmful effects. 
The main strength of this study was the robust and rigorous search strategy used to identify 
relevant articles. The included articles were scanned for additional articles which the search 
might have missed, but none were found, testifying to the thoroughness of the search 
strategy. Several limitations were identified. First, the exclusion criteria limited the search to 
English articles over a five-year period from 2014 to 2018 (this period was chosen to exclude 
articles based on technology older than five years). The included articles were all based in 
developed countries which meant that the results might not apply to developing countries 
like South Africa. Second, the small overall population size was a limitation because the meta-
analysis was likely to be underpowered and lacking the ability to detect less common perinatal 
outcomes like shoulder dystocia and stillbirth. Third, the variation in the mHealth 
technologies being tested, the screening protocols that were implemented and the local 
medical practices might have contributed to the substantial heterogeneity (I2 > 50%) in many 
of the outcomes. Fourth, there were seven articles omitted because the full text was not 
accessible. None of the omitted articles were RCTs or CCTs, so they were not expected to 
affect the results. Lastly, only one reviewer was involved in the review process so there was 
a strong likelihood of bias in the article selections. 
The biological outcomes showed that the mHealth intervention caused a statistically 
significant (P < 0.00001) decrease in overall blood glucose levels (pre-prandial and 
postprandial combined). This was different from previous systematic reviews assessing 
studies conducted prior to 2014, which found non-statistically significant evidence (P = 0.91) 
that the mHealth intervention reduced blood glucose levels in women with GD (Ming et al., 
2016, Rasekaba et al., 2015). The improved blood glucose levels might be as a result of newer 
mHealth technologies, which had become more effective due to the continuous research on 
this subject, or it might be a skewed result due to the limitations of the study. The reduction 
in blood glucose levels were likely due to women, who were using the intervention, receiving 
direct feedback from healthcare professionals, the ease of access to GD information through 
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the intervention, the monitoring of diet, weight gain and medication adherence, and the 
automated alerts and reminders that went with the mHealth interventions. 
The results showed that mHealth interventions helped women to reduce their HbA1c levels, 
which was consistent with previous systematic reviews (Lau et al., 2016, Ming et al., 2016, 
Rasekaba et al., 2015). However, the reduction in HbA1c levels found was not statistically 
significant (P = 0.48) and was based on substantially heterogenous data (I2 = 98%). The 
reduction in HbA1c levels was likely due to tighter control of blood glucose levels due to the 
use of mHealth. 
The maternal outcomes showed that the intervention successfully increased the probability 
of a normal vaginal delivery by a statistically significant amount (P = 0.02), based on 
homogeneous data (I2 = 0%). The intervention was found to cause non-statistically significant 
reductions in the probability of caesarean sections (P = 0.17), emergency caesarean sections 
(P = 0.23) and gestational hypertension (P = 0.42). All the outcomes were based on data of an 
acceptable heterogeneity, except the emergency caesarean section outcome (I2 = 66%). The 
meta-analysis found no difference in gestational ages at delivery. These findings were not in 
keeping with the previous systematic reviews which assessed maternal outcomes. Previous 
systematic reviews found mHealth to cause a non-statistically significant increase in 
caesarean sections (P = 0.41) (Lau et al., 2016, Ming et al., 2016) and gestational hypertension 
cases (P = 0.31) (Ming et al., 2016). However, Rasekaba et al. (2015) agreed with the findings 
of the current study, also finding a non-statistically significant decrease in caesarean sections 
(P = 0.37) due to mHealth. None of the previous systematic reviews that were investigated 
reported on the normal vaginal delivery rates as is done in the current study. A larger sample 
size might yield statistically significant results. 
The meta-analysis of the perinatal outcomes found that there were no statistically significant 
results for the analysis on birthweights, macrosomia rates, NICU admissions or premature 
births, as found by previous systematic reviews (Lau et al., 2016, Ming et al., 2016). There 
was, however, a statistically significant reduction in the probability of neonatal 
hypoglycaemia (P = 0.02), based on homogeneous data (I2 = 0%), which was not found in 
previous systematic reviews. Although not statistically significant, the meta-analysis also 
found a notable (P = 0.08) reduction in the probability of a premature birth due to the use of 
mHealth. A larger sample size might yield statistically significant results. 
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The cognitive outcomes were found not to be statistically significant; however, patient 
compliance was notably improved by the intervention (P = 0.06). The data was substantially 
heterogeneous (I2 = 99%) due to the possible differences in methods used to measure patient 
compliance. Patient compliance was not measured by previous systematic reviews; however, 
these systematic reviews found that mHealth motivated patients in the self-management of 
their disease (Lau et al., 2016, Ming et al., 2016, Rasekaba et al., 2015), which was a possible 
cause for the improved compliance. 
Economic outcomes were assessed by previous systematic reviews which found that mHealth 
reduced the need for face-to-face consultations and unplanned face-to-face consultations 
while achieving similar maternal and perinatal outcomes (Ming et al., 2016, Rasekaba et al., 
2015). Rasekaba et al. (2015) found two studies which reported a net cost saving for GD 
patients using mHealth. The reduction of the frequency of outpatient services was a probable 
cause for the healthcare costs for patients to be reduced. The findings from Ming et al. (2016) 
and Rasekaba et al. (2015) were supported by the current study which reported a notable, 
but not statistically significant (p = 0.19) reduction in outpatient services due to mHealth 
(although this result was based on substantially heterogeneous data (I2 = 96%)). The current 
study analysed two RCTs which reported on healthcare costs and found that one reported 
notable, but not statistically significant (no P value was reported) cost savings (Mackillop et 
al., 2018) and the other reported no difference in cost savings (Rasekaba et al., 2018) due to 
mHealth. 
It was found that the five qualitative studies (Garnweidner-Holme et al., 2018, Hirst et al., 
2015, Nicholson et al., 2016, Pais et al., 2017, Skar et al., 2018) that were assessed all reported 
that mHealth was associated with high levels of patient satisfaction which was in keeping with 
previous studies (Ming et al., 2016). The major benefits of using mHealth to manage GD 
included the convenience of digital record keeping and the time and cost effectiveness 
associated with being remotely monitored by healthcare professionals. Some of the 
challenges reported included technical difficulties associated with the use of technology and 
various data privacy concerns. 
The features and functions of the various mHealth solutions for GD were assessed and are 
presented in the results section. It must be noted that none of the mHealth solutions assessed 
functioned as a pregnancy management tool at the same time as a GD management tool. An 
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opportunity was identified which was to develop an mHealth platform for GD which 
incorporated the crucial features required for GD management (according to research), but 
which also functioned as a pregnancy management tool. 
In conclusion, mHealth has the potential to improve biological, maternal, perinatal, cognitive 
and economic outcomes, but further research is required to conclusively assess its effect on 
these outcomes. There is no evidence on the postpartum and long-term effects of mHealth 
on women who had GD, which needs to be investigated. Although many of the outcomes 
require further research in order to obtain statistically significant results, there are at least no 
negative effects caused by mHealth. Its major advantage may lie in its ability to support 
remote monitoring and reduce outpatient services, thereby reducing healthcare costs for 
patients. Its ability to motivate and educate patients may be what causes tighter glycaemic 
control, and this may lead to positive maternal and perinatal outcomes. 
The outcomes of this chapter inform the design process which is discussed in Chapter 4. The 
design uses the best features of all the existing mHealth solutions for GD and combines them 
with pregnancy-related features for a comprehensive GD mHealth platform  
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4. Design, Development and Testing of a Gestational 
Diabetes mHealth Platform 
This chapter focuses on the final objective, which uses the findings from the previous 
objectives (to assess the current gestational diabetes (GD) management practices and the 
existing mHealth solutions for GD) to direct the design, development and testing of the GD 
mHealth platform. 
4.1. Design Requirements 
The platform consists of three integrated systems: the mobile app for patients, the web app 
for healthcare professionals and the backend for administrators. Each system has its own set 
of design requirements. 
4.1.1. Mobile Application 
The mobile app was required to: 
 record personal and clinical data, including the user’s full name, identity number, 
contact details (cell phone number and email address), residential address, 
healthcare professional’s name and unique identifier, height, pre-pregnancy 
bodyweight, diabetes type and due date, 
 wirelessly interface with Bluetooth-enabled glucose meters to automatically receive 
blood glucose data,  
 track the patient’s blood glucose levels (with pre-prandial and postprandial labels), 
carbohydrate intake, activity duration, bodyweight, medication and symptoms, 
 include pregnancy specific tools and trackers, for example a blood pressure tracker 
and a due date calculator, 
 display data both graphically and numerically with colour-coded thresholds, 
 remind the patient to test blood glucose levels, take medication and attend 
scheduled appointments, 
 educate the patient on self-care and other diabetes related information, 
 allow two-way communication between patients and healthcare professionals, and 
 transmit data to a backend for remote access by healthcare professionals. 
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4.1.2. Web Application 
The web app was required to: 
 view and modify the patient’s personal and clinical information, 
 display remotely recorded data graphically and numerically for a selectable period,  
 allow notes to be recorded, 
 alert healthcare professionals of patients who are not meeting clinical goals, 
 read and write messages to and from patients, 
 view and schedule consultations, and 
 only allow authorised access to private data. 
4.1.3. Backend 
The backend was required to: 
 be scalable, 
 store all data securely and privately, 
 allow administrators to manage all users, 
 allow administrators to make live updates to the mobile app and web app, and 
 allow the administrator to send out push notifications. 
4.2. Frontend Design 
The description of the design is divided into two sections: the first section discusses the design 
of the mobile app and the second section discusses the design of the web app. The various 
design requirements are discussed using “art boards” of the design for illustrative purposes. 
4.2.1. Mobile Application Design 
The mobile app was designed primarily as a GD self-management tool for patients to reduce 
the frequency of outpatient services required and improve glycaemic control, among other 
things. It served a secondary purpose as a pregnancy tracker. Pregnancy related features were 
added to the prototype of the mobile app during the development phase. 
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Figure 4.1 shows the chosen colour palette, generated using Material Palette (Material 
Palette, 2019). The shades of purple were chosen based on the femininity associated with it. 
Green was chosen as an accent colour because of the positivity associated with it. The colour 
palette was manually implemented during the design phase. Because Android Studio could 
associate a theme with user defined colours, which it automatically applied, the colour palette 
was only fully implemented during the development phase.  
 
Figure 4.1: Colour palette 
  
Hex code: #7B1FA2 
Hex code: #9C27B0 
Hex code: #E1BEE7 
Hex code: #FFFFFF 
Hex code: #4CAF50 
Hex code: #212121 
Hex code: #757575 
Hex code: #BDBDBD 
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Figure 4.2 shows the design of the mobile landing board. The platform was named 
“GooDMoM”, derived from the acronym GDMM (Gestational Diabetes Mobile Management), 
because of its purpose as a GD management tool. The name was chosen to represent soon-
to-be mothers, who were motivated to manage their disease to prevent adverse outcomes 
for themselves and their children, thus being “good moms”.  
 
Figure 4.2: Mobile landing board 
4.2.1.1. Mobile Sign-up Design 
The sign-up process was designed to record the account details, personal details and clinical 
details, as specified in the design requirements. The design allowed accounts to be created 
using the patient’s full name and was intended to link to the patient’s email address. This 
decision was made because email-based accounts were safer than cell phone number-based 
accounts since a stolen cell phone could be used to hijack a patient’s cell phone number-
based account. An email-based account should allow the account owner to change account 
details via email by using a separate device (if the primary device was stolen), thus providing 
better security. Figure 4.3 shows the design of the first mobile sign-up board, which records 
the patient’s account details. 




Figure 4.3: Mobile sign-up board 1 
The second stage of the sign-up process was designed to record the personal details of the 
patient, including the patient’s full name and identity number, which would be used to 
validate the patient and ensure that each patient was associated with only one account. If the 
patient had data stored on another database, the data could be merged with the GooDMoM 
database based on the patient’s identity number. The personal details board was also 
designed to record the patient’s cell phone number so that the patient could be contacted via 
a phone call and the patient’s home address details so that medical assistance could be sent 
to the patient if necessary. Figure 4.4 shows the design of the second mobile sign-up board, 
which records the patient’s personal details. 
 




Figure 4.4: Mobile sign-up board 2 
The third stage of the sign-up process was designed to record the clinical details, which 
included the healthcare professional’s name and user identification code. The healthcare 
professional’s user identification code would provide the programmatic link between the 
patient and her healthcare professional, while the surname should allow administrators to 
identify the patient’s healthcare professional if the patient mistyped the user identification 
code. The clinical details board was also designed to record the patient’s height and pre-
pregnancy bodyweight which would be required to calculate the patient’s body mass index 
(BMI). The diabetes type would give the linked healthcare professional an indication of how 
to treat the patient and an indication of the extent of the patient’s pre-existing knowledge 
about the management of diabetes. The due date would be recorded so that patient’s 
healthcare professional could evaluate the patient’s biological measures based on her stage 
of gestation and the patient could use it as a motivating goal to aim for. The prototype of the 
mobile app would include a due date calculator to allow women to accurately estimate their 
due date. Figure 4.5 shows the design of the third mobile sign-up board, which records the 
patient’s clinical details. 




Figure 4.5: Mobile sign-up board 3 
4.2.1.2. Mobile Dashboard Design 
Figure 4.6 shows the design of the mobile “feed” board. The “feed” (renamed to “dashboard” 
during development) was designed to display all recorded data. As specified in the design 
requirements, the data was depicted graphically (in the form of a line graph) and numerically 
(in the form of averages for the selected period). A line graph was chosen because it allowed 
trends to be visualised. Displaying the numerical values as averages, as opposed to listing the 
value of each entry, simplified the amount of data on the screen, which would be particularly 
useful on smartphone screens which were relatively small compared to computer screens. 
The data of each individual entry would be viewable through a pop-up screen by clicking on a 
data point on the line graph; however, this would only be implemented during the 
development of the prototype. The line graph was designed to display the healthcare 
professional-specified target range so that the patient could clearly see when she was not 
meeting her targets. In the development phase, out of target values would be displayed in a 
different colour to draw attention to them. 




Figure 4.6: Mobile feed board 
Figure 4.7 shows the design of the data entry board. As specified in the design requirements, 
the mobile app should record blood glucose levels, carbohydrates, activity duration, 
bodyweight, blood pressure, medication and symptoms. It was decided that there should be 
one data entry screen for all measurements, as opposed to having separate screens for each 
measurement type. The decision was made in order to maintain the simplicity in navigating 
the mobile app. 
Blood glucose levels were intended to be recorded digitally by the mobile app, which patients 
found easier than recording on paper, as revealed in the Chapter 3 review of existing mHealth 
solutions for GD. In the prototype of the mobile app, the blood glucose levels would be 
transferred from the glucose meter to the mobile app via Bluetooth by tapping the 
synchronise icon. Blood glucose levels could be entered manually if there was a problem with 
the Bluetooth transfer, but would be programmatically marked as manual so that the 
patient’s healthcare professional would know that the data might not be trustworthy. The 
point of automatically entering the results was to avoid accidental or purposeful errors in 
recording, as mentioned in Chapter 3. All blood glucose recordings would be associate with a 
time, a date, whether they were pre-prandial or postprandial, and a location. Users would be 
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asked to specify when their reading was taken in relation to a meal, for example “after lunch” 
or “before supper”. In the prototype, the readings would be programmatically categorised as 
pre-prandial or postprandial based on when they were taken. Reviewing blood glucose data 
in terms of pre-prandial and postprandial readings could allow healthcare professionals and 
patients to identify the effects of meals on blood glucose data. Separating pre-prandial and 
postprandial blood glucose readings would also prevent unnecessary alarm when comparing 
the different types of readings (for example, postprandial blood glucose readings should be 
expected to be notably higher than pre-prandial blood glucose readings, but an ignorant 
patient might be alarmed when seeing the difference). The location was designed to be 
recorded via a drop-down menu which would give certain options, including “home” and 
“work” as examples. This should be recorded so that certain trends that might be associated 
with the patient’s location at the time of recording could be identified. 
The data entry board was designed to record the details of the patient’s diet in the form of 
an estimate of the amount of carbohydrates consumed as well as a description of the meal. 
By clicking on the drop-down arrow, the patient would also be able to choose the food type 
and the number of portions consumed, as opposed to manually entering the meal, for ease 
of use. Carbohydrates should be tracked specifically because they could have a large effect 
on blood glucose levels, as mentioned in the Chapter 2 review of existing GD management 
practices. The app was designed to facilitate the manual tracking of the patient’s activity 
duration and allowed the patient to provide a description of the activity. As described in 
Chapter 2, activity data should be tracked because of its importance in reducing blood sugar 
levels and enabling the body to use insulin. Bodyweight should be tracked because 
maintaining a healthcare professional-recommended bodyweight was important to the 
management of GD and pregnancy. Blood pressure should be monitored for healthcare 
professionals to detect the onset of gestational hypertension and provide the necessary 
treatment. Pills, renamed as medication during the development phase, should be tracked so 
that the healthcare professional could monitor the patient’s compliance in taking prescribed 
medication. Lastly various symptoms experienced by the patient would be tracked via a drop-
down menu, which could be used by healthcare professionals in making diagnoses and 
prescribing medication. 




Figure 4.7: Mobile data entry board 
4.2.1.3. Mobile Reminders Design 
The reminders were designed to remind the patient to test blood glucose levels, take 
medication and attend appointments. Alerts and reminders were one of the benefits of using 
an mHealth platform to manage GD, as seen in Chapter 3. Chapter 3 also showed that 
mHealth increased the level of patient compliance regarding measuring blood glucose levels. 
This was largely due to the reminders and alerts used in the various mHealth platforms, hence 
the reason why the feature was included in this design.  
Figure 4.8 shows how the reminders board displays the events. The board was designed to 
list the events in chronological order and display just the event title, time and date for 
simplicity purposes. The additional information could be viewed or edited by tapping on the 
relevant event in the prototype. 




Figure 4.8: Mobile reminders board 
Figure 4.9 shows the design for the reminder entry board. It was found that patients needed 
to be reminded to measure their blood glucose levels, take their medication and attend 
scheduled appointments, as specified in the design requirements. Patients would be required 
to title their reminder for identification purposes and choose the reminder type. The patient 
should select the time of the event and choose a repeat. The repeats were especially useful 
for medication and glucose measurement reminders which would need to repeat daily, but 
also apply to appointment reminders which might need to repeat every 1 to 4 weeks. The 
patient could also enter a location if the reminder was for an appointment and additional 
notes could also be added. 




Figure 4.9: Mobile reminder entry board 
4.2.1.4. Mobile Messenger Design 
Having a two-way communication channel was found in the literature review of chapter 3 to 
be a major benefit of using mHealth in the management of GD, because it allowed patients 
to receive feedback from healthcare professionals regarding their progress and further 
allowed patients to ask healthcare professionals questions. Figure 4.10 shows the design of 
the mobile messenger board. 




Figure 4.10: Mobile messenger board 
4.2.1.5. Mobile Tips Design 
The fact that mHealth platforms allowed easy access to GD related information was cited as 
a major benefit in chapter 3. It allowed the patient to review the information wherever and 
whenever she wanted and prevented the patient from misinterpreting or forgetting 
information issued by healthcare professionals at an appointment. However, there were 
concerns that the information supplied by mHealth platforms did not always match the 
information supplied by healthcare professionals. The information was often too general and 
the information was not culturally inclusive. The benefits were deemed to outweigh the 
challenges, so it was decided that the tips section should be included. 
Figure 4.11 shows the design of the mobile tips board, named “Tips and Tricks”, but renamed 
to “Tips” during development for simplicity purposes. The tips board was designed to display 
each tip as an image with a title and a timestamp, similar to news apps. The patient would be 
able to open the article by tapping on the relevant tip. This feature of the mobile app was 
designed to work with a custom-built GD database of information, which would target South 
African women with GD related information based on their stage of gestation.   




Figure 4.11: Mobile tips board 
4.2.1.6. Mobile UX Design 
Figure 4.12 depicts the mobile UX design. It shows the artboards as “frames” with “wires”, 
which indicate the flow between one and another as a result of user interaction.  
The design of the UX was focused on simplicity and usability, in line with current practices for 
mHealth apps (Stoyanov et al., 2015). Stoyanov et al. (2015) developed a tool for assessing 
the quality of mHealth apps and determined that functionality (which directly affects UX) was 
one of the categories of importance. The functionality was influenced by the performance, 
ease of use, navigation and gestural design of the app (Stoyanov et al., 2015). As such, these 
were all key areas in the design process.  
Regarding the functionality of the GooDMoM mobile app, a bottom navigation bar was used 
to navigate through the features of the mobile app. This was chosen, because it clearly 
displayed the main features of the mobile app, maintaining the simplicity and promoting 
intuitive use. Bottom navigation bars were ideal for those with smaller hands, because it was 
suited to one-handed navigation, which was necessary on large screen smartphones. This 
suited the population to which this mobile app was aimed.  




Figure 4.12: Mobile UX 
4.2.2. Web Application Design 
The web app was designed for healthcare professionals to remotely monitor their patients I 
real-time, improving the ease of access to patient data, as specified in the design 
requirements.  
Figure 4.13 shows the design for the home board. The colours shown in Figure 4.1 and the 
name of the platform were maintained for uniformity purposes. To access the home page, 
healthcare professionals would be required to sign-in (this would only be implemented during 
development of the prototype). This satisfied the design requirement to only allow authorised 
personnel to access private data. 
The design of the linked patient database board is shown in Figure 4.14. This board is designed 
to display all of the patients who are linked to the signed in healthcare professional. Each 
patient’s full name and display picture would be displayed. The healthcare professional could 
click on a patient’s name or display picture to access her data. 
Figure 4.15 shows the personal details board. It was called “personal details” but was 
renamed to “patient details” during development to avoid confusion. It was designed to 
display and modify the personal and clinical information entered by the patient during the 
sign-up process, including the patient’s full name, identity number, email address, cell phone 
number, residential address, date of birth (derived from the first six numbers of the identity 
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number), due date, diabetes type pre-pregnancy bodyweight, height and BMI. The reason 
why these specific personal and clinical details were focused on was discussed in section 4.2.1. 
The linked healthcare professional should able to set the patient’s blood glucose level goals, 
bodyweight goals and activity duration goals (this would only be implemented during 
development of the prototype). These goals would be displayed to the patient on her mobile 
app. It was necessary that the healthcare professional set the goals digitally so that the patient 
could determine when she was out of range when viewing her results (there would be an 
automatic colour change for an out of range data point as mentioned in section 4.2.1.). Setting 
the goals digitally also meant that there could be no misinterpretation due to a 
misunderstanding or any other similar problem. Lastly, the healthcare professionals would 
also be able to add comments for their own benefit. 
Figure 4.16 shows the design of the digital patient history board. The design of the form was 
based on the standard form used for patients. Data from existing electronic health records 
should be able to be copied to the GooDMoM database. If patients filled out a paper form, a 
healthcare professional or an assistant would copy the information to the digital form. An 
electronic health record was important, because it would allow patients to transfer between 
medical facilities and between healthcare professionals without the hassle of transferring or 
refilling forms. It also meant that there would be a history of changes made to the form.  
Lastly, electronic health records could not be lost like paper-based forms can. 
The design of the web feed board (renamed to dashboard during development) is shown in 
Figure 4.17. The ability to analyse patient data in real-time was found in Chapter 3 to be a 
major benefit for healthcare professionals using a GD mHealth platform. The healthcare 
professional’s feed was designed to mimic the patient’s mobile app-based feed, allowing 
healthcare professionals to view blood glucose levels, carbohydrates, activity duration, 
bodyweight, blood pressure and medication adherence. The data could be viewed by day, by 
month or by the full gestational period. Blood glucose data could be separated into pre-
prandial and post prandial. During development, functionality to display the data in numerical 
form, add notes where necessary, view symptoms associated with various readings and alert 
the healthcare professional of patients who were not meeting goals (which was identified as 
a benefit of GD mHealth platforms in Chapter 3) would be added to satisfy the design 
requirements. 
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Figure 4.18 shows the design of the messenger board. This board was designed to allow 
healthcare professionals to communicate directly with their patients by sending and receiving 
messages, as specified in the design requirements. The messenger should allow healthcare 
professionals to provide feedback on the patient’s data and answer the patient’s GD-based 
questions, which patients identified as a major benefit of using a GD mHealth platform in 
Chapter 3. 
Figure 4.19 shows the design of a calendar board. The design requirements specified that the 
healthcare professional should be able to view and schedule consultations with their linked 
patients. Appointments scheduled by linked patients would be displayed and healthcare 
professionals should be able to schedule and view appointments. Keeping a digital record of 
appointments would be beneficial, because the digital platform would be able to remind the 
various parties of the appointment. It would also prevent miscommunication and it would 
keep records of all past appointments. During development, functionality would be added to 
allow healthcare professionals to add appointment notes and to mark whether the patient 
attended or not.  
Figure 4.20 shows the designed web UX. The web UX followed the simplicity which was at the 
core of the design of the mobile app and web app. The simplicity was necessary because one 
of the challenges associated with GD mHealth platforms, as found in Chapter 3, was to 
convince healthcare professionals to use the new technology. A simple UX would go a long 
way toward achieving this. 




Figure 4.13: Web home board 
 
Figure 4.14: Web patient database board 




Figure 4.15: Web patient personal details board 
 
Figure 4.16: Web patient history board 
 




Figure 4.17: Web feed board 
 
Figure 4.18: Web messenger board 




Figure 4.19: Web calendar board 
 
Figure 4.20: Web UX 
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4.3. Testing of the High-Fidelity Mock-up 
The high-fidelity mock-up was tested in the form of a usability study. The main goal of the 
usability study performed on the high-fidelity mock-up was to get feedback on the UI design.  
The secondary goal was to test the UX of the high-fidelity mock-up. The outcomes of the 
usability study were applied to the development of the prototype. 
The questionnaire used to gauge the usability of the high-fidelity mock-up can be seen in 
Appendix A. The results of the study are given below in two sections, one for the mobile app 
and one for the web app. 
4.3.1. Demographics of participants 
For this usability study, 14 applicable participants were identified and willing to participate, 
all part of the Biomedical Engineering Division at the University of Cape Town. Of the 14 
participants to whom the study was sent, 10 replied. The 10 participants had an average age 
of 29.7 years and were 70% male and 30% female. The small population size was deemed 
adequate, because the study was based on an early stage of development which required 
brief feedback in order to continue with development. 
Table 4.1 displays the results of the pre-task questions in tabular form. The pre-task questions 
were designed to gauge the level of knowledge of the participants in terms of technology-
based knowledge and diabetes-based knowledge.  
 
Table 4.1: Pre-task questions (high-fidelity mock-up) 
1. On a scale of 1 to 5 (1 = not at all confident, 5 = very confident), how would you rate 
your level of confidence in using your mobile phone. 
 1: 0%  2: 0%  3: 0%  4: 30%  5: 70% 
2. On a scale of 1 to 5 (1 = not at all knowledgeable, 5 = very knowledgeable), how would 
you rate your level of knowledge about diabetes? 
 1:  0%  2: 30%  3: 50%  4: 10%  5: 10% 
3. How many times per day do you test your blood glucose levels? 
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1 = Never, 2 = Rarely (once per week), 3 =Occasionally (2-3 times per week), 4 = Frequently 
(1-2 time per day), 5 = Very Frequently (3+ times per day) 
 1:  80% 2: 20%  3: 0%  4: 0%  5: 0% 
4. Have you used an app to track your blood glucose levels (if you have diabetes)? 
 Yes: 0%  No: 100% 
 
Based on the pre-task questions seen in Table 4.1, it could be noted that the group of 
participants were all confident in the use of their mobile phones, with the majority rating 
themselves as very confident (70% of participants). The level of knowledge about diabetes 
was spread, with the majority (50% of participants) having an average knowledge. Only 20% 
of the participants had tested their blood glucose levels, albeit rarely. Of those participants, 
none of them had ever used an app to track their blood glucose levels. The participants were 
thus technologically proficient, with an average to low knowledge of diabetes. This should be 
considered when analysing the data, because the target market might not have the same 
characteristics. 
4.3.2. Mobile Application Usability 
The 10 participants were given a list of tasks and were asked to fill out a usability 
questionnaire after they finished the list of tasks. 
 Table 4.2 displays the results of the tasks to be completed in tabular form and Table 4.3 
displays the results of the post-task questions in tabular form. The results are discussed 
below. 
Table 4.2: Tasks to be completed (mobile high-fidelity mock-up) 
Task Percentage of Users Who 
Completed the Task 
1. Sign-up 100% 
2. View the feed  100% 
3. Sign out 100% 
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4. Sign-in  100% 
5. Add a reminder (appointment, medication or glucose 
reading) 
100% 
6. Enter data (glucose reading, meal, activity, bodyweight, 
medication, blood pressure, symptoms) 
100% 
7. Synchronise data with glucose meter on data entry 
screen 
100% 
8. Send a message to healthcare professional 100% 
9. View “Tips and tricks” articles 100% 
10. Go to settings 
10.1. View profile 





Table 4.3: Post-task questions (mobile high-fidelity mock-up)  
1. On a scale of 1 to 5 (1 = negative, 5 = positive), how would you rate the ease of your 
experience with the GooDMoM app? 
 1:  0%  2: 0%  3: 0%  4: 40%  5: 60% 
2. On a scale of 1 to 5 (1 = unsuitable, 5 = suitable), how suitable did you think the 
GooDMoM name was for the platform? 
 1:  0%  2: 10%  3: 20%  4: 40%  5: 30% 
3. On a scale of 1 to 5 (1 = unattractive and inappropriate, 5 = attractive and 
appropriate), how would you rate the colour scheme of the app? 
 1:  0%  2: 10%  3: 10%  4: 20%  5: 60% 
4. On a scale of 1 to 5 (1 = cluttered and confusing, 5 = well-spaced and easily 
understandable), how would you rate the layout of the app? 
 1:  0%  2: 0%  3: 10%  4: 10%  5: 80% 
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5. Did you have any navigational issues?  
 Yes: 20% No: 80%  
6. Which feature did you think was most important? 
1 = The feed, 2 = The reminders, 3 = The data capture, 4 = The messenger, 5 = The tips and 
tricks 
 1:  50% 2: 20%  3: 30%  4: 0%  5: 0% 
7. Were there any features you did not understand?   
 Yes: 10% No: 90% 
 
Detailed instructions were given to each participant on how to complete each task (as seen 
in the usability study questionnaire in Appendix A). According to Table 4.2, 100% of 
participants were able to successfully complete each task 
According to Table 4.3, the general experience of the mobile app was positive with 60% of 
participants rating their experience as highly as possible. Participants also praised the UI 
design, especially the colour scheme with 60% of participants giving the app the highest rating 
for attractiveness and appropriateness. Regarding the layout, 80% of participants awarded 
the highest level for spacing and understandability. However, there was mixed feedback 
about the suggested name, “GooDMoM”, which stands for Gestational Diabetes Mobile 
Management. It was suggested that the name might imply that women who do not use the 
app were bad mothers, which was not necessarily the case. A name change could be 
considered at a later stage. 
A few participants were specifically impressed with the bottom navigation, which makes one-
handed navigation possible, no matter the size of the screen. However, 20% of the 
participants had navigational issues as seen in Table 4.3. These issues were a result of only 
the icons in the bottom navigation bar being clickable, not the text as well. This should be 
rectified in the prototype. 
With regard to the sign-up process (seen in Figure 4.3, Figure 4.4 and Figure 4.5), the feedback 
from the participants suggested that only the email address, the identity number, the cell 
phone number and the healthcare professional’s unique identifier should be mandatory. The 
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user should be able to complete the other fields at a later stage so that users who did not 
know all their details during the sign-up would not be unnecessarily lost. These fields were 
suggested to be mandatory because the email address was needed for account creation, the 
identity number was necessary to ensure that each patient could only have one account, the 
cell phone number was needed for contact purposes and the healthcare professional’s unique 
identifier was needed to link the patient to a specific healthcare professional. It was suggested 
that when the patient typed in a certain healthcare professional’s unique identifier, that 
healthcare professional should first accept the request on the web app before the link was 
formed for security and privacy purposes. 
Based on the feedback received from participants, the feed (seen in Figure 4.6), which 
graphically displayed the patient’s data was deemed the most important feature of the app 
(as agreed upon by 50% of the participants), according to Table 4.3. However, participants did 
mention that the numbers on the axes should be made bigger and grid lines should be 
included on the graph. It was recommended by a few participants that data points should 
change colour based on whether they fall within the healthcare professional’s specified range 
or not. The word “feed” should also change to “dashboard”, which would be a better fit for a 
screen that displays data. 
With regard to the reminders boards (seen in Figure 4.8 and Figure 4.9), participants pointed 
out that there should be functionality to view and edit events which have already been 
created. The design for the display of events was only updated after this usability study was 
conducted. It was mentioned that the app should be able to export reminders to a dedicated 
calendar app on the user’s phone. There should also be consistency in the use of the word 
“medication”, as opposed to “pills” which is less generic, throughout the platform.  
The main concern with the data entry board (seen in Figure 4.7) was that the name in the 
navigation bar (“data”) suggested that data could be viewed there, but the icon suggested 
that data could be added there. The contradiction between the icon and the text should be 
rectified in the prototype. It was suggested that there should be a dedicated dashboard, 
which would allow patients to view their data graphically and provide access to the data entry 
screen, as opposed to providing direct access to the data entry screen in the navigation bar. 
According to Table 4.3, 10% of the participants did not understand the data entry process, 
pointing out that the method of adding data was confusing. The reason was that it was unclear 
Jason Leslie Collier University of Cape Town 12 January 2020 
72 
 
whether the user should fill in all the data fields every time or if the user could fill in only 
specific data fields at a time. These concerns should be addressed in the development of the 
prototype. 
The feedback regarding the messenger (seen in Figure 4.10) advised that the associated icon 
be changed to a text bubble instead of a letter, as letters were seen as more formal than text 
bubbles. This could influence patients against contacting their linked healthcare 
professionals.  
4.3.3. Web Application Usability 
The web app usability study was sent to the 10 participants who replied to the mobile app 
usability study. There were 6 replies from the 10 who were sent the study.  
Table 4.4 shows the percentage of users who were able to complete the task given to them 
while using the high-fidelity mock-up. Table 4.5 displays the post-task feedback from 
participants. The results are discussed below. 
Table 4.4: Tasks to be completed (web high-fidelity mock-up) 
Task Percentage of Users Who 
Completed the Task 
1. Log in  100% 
2. View the patient database 100% 
3. View a specific patient 100% 
4. View the patient’s personal details, patient history and 
dashboard 
100% 
5. View the messenger  100% 
6. View the calendar 100% 
7. View the Home screen 100% 
 
Table 4.5: Post-task questions (web high-fidelity mock-up) 
1. On a scale of 1 to 5 (1 = negative, 5 = positive), how would you rate the ease of your 
experience with the GooDMoM web app? 
 1:  0%  2: 0%  3: 17%  4: 0%  5: 83% 
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2. On a scale of 1 to 5 (1 = cluttered and confusing, 5 = well-spaced and easily 
understandable), how would you rate the layout of the web app? 
 1:  0%  2: 0%  3: 0%  4: 33%  5: 67% 
3. Did you have any navigation issues?  
 Yes: 17% No: 83% 
4. Was there any functionality you believe needs to be added? 
 Yes: 0% No: 100% 
 
Detailed instructions were given to each participant on how to complete the task (as seen in 
the usability study questionnaire in Appendix A). Table 4.4 shows that 100% of participants 
were able to successfully complete each task. 
According to Table 4.5, 83% of participants rated their experience with the web app as 
positively as possible. Regarding the layout of the web app, 67% of users highly rated the app 
as well-spaced and understandable. 
There were a few minor navigational issues in the web app, experienced by 17% of the 
participants, according to Table 4.5. The first issue with the navigation was that there was no 
clear home button – the platform name was not an intuitive home button. It was noted from 
the feedback that all scrollable pages needed a vertical scrollbar. When scrolling, the header 
should be fixed to the top of the screen. The last issue with the navigation was that the text 
in the header was too small. These issues should be addressed in the prototype. 
The participants agreed unanimously that there was no functionality which needed to be 
added to the web app, according to Table 4.5. This meant that, according to the participants, 
the web app had the core features which it required to satisfy its objective. 
On the calendar board (seen in Figure 4.19), the days which did not fall into the month in view 
should be faded out in order to avoid confusion in the prototype. The healthcare professional 
should have the option to add appointments to his or her email-linked digital calendar 
according to participants’ feedback. 
The feedback regarding the messenger (seen in Figure 4.18) advised that the healthcare 
professional be alerted to new messages in some way. This should be included in the 
prototype in the form of email alerts or via web pop-ups. 
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There was some general feedback, based on the platform as a whole. Participants pointed out 
that the font in a few areas was too small and should be rectified in the prototype. It was 
mentioned that more contrasting colour should be added. Human images should be added to 
make the app easier to identify with for pregnant women. Lastly, more pregnancy related 
features should be added during development of the prototype, like a due date progress bar. 
4.4. Backend Development 
The backend used Firebase as a service to authorise users and store data securely. It was 
found that Firebase provides scalability, allows administrators to manage all users, allows 
administrators to make live updates to the mobile app and web app, and allows the 
administrator to send out important push notifications as specified in the design 
requirements (Firebase, 2019a). Firebase offered the necessary security and privacy for the 
data stored on its servers, as shown in their security practices:  
 Firebase restricted and logged access to systems that contained personal data 
(Firebase, 2019b). 
 Firebase only permitted access to personal data by those who signed in with Google 
Sign-In and 2-factor authentication (Firebase, 2019b). 
 Firebase encrypted data during transfer (Li et al., 2018). 
Figure 4.21 shows the list of authorised users on the backend (populated for demonstration 
purposes). Figure 4.22 shows the database containing all the stored data, which is in JSON 
format. 
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Figure 4.21: Backend user list 
 
Figure 4.22: Backend database 
4.5. Frontend Development 
The frontend was developed using the Android Studio IDE. The frontend development was 
influenced by the high-fidelity mock-up’s UI and UX design as well as feedback from the 
usability study done on the high-fidelity mock-up.  
The description of the development is divided into two sections: one section for the mobile 
app and the other for the web app. 
4.5.1. Mobile Application 
Each phase of the development of the mobile app is detailed separately, with screenshots 
and a description relating to that phase. 
4.5.1.1. Sign-Up and Sign-In 
Figure 4.22 shows the mobile landing screen. Figure 4.23, Figure 4.24 and Figure 4.25 show 
the 3-step mobile sign-up process. 
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Patients were required to sign-up with an email address as seen in Figure 4.23. If the email 
entered already had an account associated with it, the patient would be asked to enter a 
password to sign-in. The personal details entry screen required patients to record their 
identity number (in order to be validated) and cell phone number (so that the patient could 
be contacted) as seen in Figure 4.24. It was optional, but recommended, that the patient 
recorded her home address so that medical assistance could be sent if necessary. The last 
screen in the sign-up process, seen in Figure 4.25, recorded clinical details, like the patient’s 
healthcare professional’s details, including the unique identification code (in order to link the 
patient to their healthcare professional programmatically). This screen also recorded the 
patient’s height, pre-pregnancy bodyweight, diabetes type and due date (the due date 
calculator is shown in Figure 4.34), which were all required fields for the patient to be profiled. 
The information gained in the sign-up process was displayed to the healthcare professional 
as seen in Figure 4.38. 
 
Figure 4.23: Mobile landing screen 




Figure 4.24: Mobile sign-up screen 1 
 
Figure 4.25: Mobile sign-up screen 2 




Figure 4.26: Mobile sign-up screen 3 
4.5.1.2. Dashboard 
The dashboard (as seen in Figure 4.26) displayed the recorded data, including blood glucose 
levels, carbohydrates, activity time, bodyweight, blood pressure and pregnancy progress. The 
data to be displayed could be chosen via a drop-down menu and the period (day, month or 
gestational period) of the data to display could be selected. The data was displayed in green 
if it was within the range specified by the patient’s healthcare professional, red if it was above 
range and blue if it was below range. A dialog was displayed if a data point was selected, 
which showed additional information associated with that data point, like the symptoms that 
the user associated with that reading (seen on the right of Figure 4.27). This data was 
synchronised with the linked healthcare professional’s web app via the Firebase backend so 
that the patient could be monitored remotely and in real-time (see Figure 4.39).  
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Figure 4.27: Mobile dashboard screen  
Data could be added via the mobile data entry screen seen in Figure 4.27. Blood glucose data 
could be recorded by clicking on the synchronise icon or the “0.0 mmol/L” text at the top of 
the screen. All blood glucose data should be labelled in relation to the nearest meal, for 
example “before meal” or “2 Hr after meal”, which would be saved programmatically as pre-
prandial and postprandial so that healthcare professionals could view the pre-prandial and 
postprandial data separately. Meal data, activity data, bodyweight data, and blood pressure 
data could be manually entered. The patient could also record that they had taken the 
medication from a list of pre-entered (by the healthcare professional) prescribed medications. 
Symptoms experienced by the patient at the time of data entry could be selected from a list 
of common symptoms shown in a dialog box which displayed when the user tapped the 
symptoms text box. Each data entry allowed the patient to record the time and location of 
the entry too.  
The ability to automatically transfer data from a glucose meter via Bluetooth was not 
successfully implemented. The app was able to scan for and connect to a Bluetooth-enabled 
glucose meter but was not able to make sense of the data. To do this, permission and 
assistance would be required from the glucose meter’s developer but had not been acquired. 




Figure 4.28: Mobile data entry screen 
4.5.1.3. Reminders 
The mobile reminders screen presented a list of manually entered reminders as seen in Figure 
4.28. Appointment reminders, glucose test reminders and medication reminders were all 
supported. The displayed reminders were green if the patient fulfilled them and red if the 
patient did not. The reminders alerted the patient on the patient’s device (in the form of a 
notification, of which the settings can be modified in the settings screen) at a user-chosen 
time before the event was to occur. The appointment reminders synchronised with the linked 
healthcare professional’s web app via the Firebase backend (as seen in Figure 4.40). All 
reminders could be selected to see more details or to edit if necessary. 
The mobile reminder entry screen shows how reminders were added (as seen in Figure 4.29). 
The patient could enter a title, select the reminder type, choose the start and end dates and 
times, add a repeat, enter a location, enter a description, choose the notification time and 
export the event to another calendar app on the phone. In a future iteration, the app should 
also automatically generate a series of necessary antenatal care and GD-related 
appointments to take place throughout the gestational period. 




Figure 4.29: Mobile reminders screen 
 
Figure 4.30: Mobile reminder entry screen 




The messenger screen, seen in Figure 4.30, provided a direct line of communication between 
the healthcare professional (as seen in Figure 4.37) and the patient. The patient could use this 
as a channel to ask for advice directly and the healthcare professional could offer feedback or 
use this to intervene remotely if the healthcare professional noticed any warning signs while 
monitoring the patient’s data. The patient would be alerted to new messages in the form of 
a notification (the settings of which could be modified in the settings screen). 
 
Figure 4.31: Mobile messenger screen 
4.5.1.5. Tips 
The tips screen (seen in Figure 4.31)  was intended to serve as a GD and pregnancy educational 
database which could be displayed to the patient in the form of written posts. Each post 
should be displayed at the necessary point during the patient’s gestational timeline. The posts 
should inform the patient on what to expect at various points during her pregnancy and how 
to handle her diabetes (among other topics). 
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This educational database had not yet been created, so the screen was showing blog posts 
from various diabetes and pregnancy feeds which had a rich site summary (RSS) feed. The 
posts could be opened in the mobile app through a web view (seen on the right of Figure 
4.32).  
      
Figure 4.32: Mobile tips screen 
4.5.1.6. Settings 
The settings screen (seen on the left of Figure 4.33) allowed the patient to edit the display 
name and notifications. The help and feedback screen (seen on the right of Figure 4.33) 
allowed the patient to view the app version, copyright details and send an email to the 
administrator. 
The edit profile screen (seen in Figure 4.34) allowed the patient to add or change the linked 
healthcare professional. It also allowed the patient to add or update her personal and clinical 
details, as well as view healthcare professional selected goals for blood glucose levels, activity 
time, carbohydrates and bodyweight. The screen gave access to the due date calculator (seen 
on the right of Figure 4.34) and showed the healthcare professional prescribed medication. 
The pre-pregnancy weight and height were used to calculate and display the patient’s BMI. 
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Figure 4.33: Mobile settings and help & feedback screens 
      
Figure 4.34: Mobile profile screen 
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4.5.2. Web Application 
Each phase of the development of the web app will be detailed separately, with screenshots 
and a description relating to that phase. 
4.5.2.1. Sign-Up and Sign-In 
The healthcare professional sign-up process was initiated by the healthcare professional and 
verified by the administrators of the platform. Once signed up, the healthcare professional 
could sign-in via email as seen in Figure 4.35. This took the healthcare professional to the 
home page as seen in Figure 4.36, from which the other pages could be navigated to. 
 
Figure 4.35: Web sign-in page 
 
Figure 4.36: Web home page 




The patients’ page, seen in Figure 4.37, displayed all the patients linked to the signed in 
healthcare professional. When a patient entered a healthcare professional’s user ID during 
the patient’s sign-up process, the healthcare professional would receive a notification which 
he or she could accept for the link to be made or decline for the link not to be made. The 
healthcare professional could select a patient which would load that patient’s data. 
 
Figure 4.37: Web patient list page 
4.5.2.3. Messenger, Patient Details, Patient History and Dashboard 
The messenger (Figure 4.38), patient details (Figure 4.39), patient history and dashboard 
(Figure 4.40) pages could be accessed by loading a specific patient’s data. These pages 
displayed confidential information that only the patient and linked healthcare professional 
should access. The selected patient’s name was displayed on the side navigation bar as seen 
in these figures. 
The messenger page, as seen in Figure 4.37, provided a direct line of communication between 
the healthcare professional and the selected patient. The patient could use this to ask for 
health-related advice and the healthcare professional could use this to intervene remotely if 
there were warning signs in the patient’s data. Healthcare professionals could also use the 
messenger to provide feedback on the patient’s progress. 




Figure 4.38: Web messenger page 
The patient details page (seen in Figure 4.38) displayed the selected patient’s personal and 
clinical details, as entered during the patient’s sign-up (seen in Figure 4.23, Figure 4.24 and 
Figure 4.25). The patient’s pre-pregnancy weight and height were used to calculate and 
display the patient’s BMI. The healthcare professional could set target ranges for the selected 
patient’s blood glucose levels, bodyweight, carbohydrates and activity duration. It also 
allowed the healthcare professional to remotely choose the medication that the selected 
patient should use. 
 
Figure 4.39: Web patient details page 
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The patient history page was an online form based on the patients’ medical history. This was 
like an electronic health record. The healthcare professional or an assistant would copy 
information from a paper-based form into the electronic health record. Functionality should 
be added to receive data from another database which had a specific patient’s health record. 
However, this page was not developed, because it was deemed unnecessary since electronic 
health records already exist. 
The dashboard page (seen in Figure 4.40) allowed the healthcare professional to remotely 
monitor the recorded data in real-time (as seen in Figure 4.28), including blood glucose levels, 
carbohydrates, activity time, bodyweight, blood pressure and medication adherence. The 
period (day, month or gestational period) of the data to display could be selected. The data 
was displayed in green if it was within the HP specified range, red if it was above range and 
blue if it was below range. The colour changes were done in order to alert the healthcare 
professional. Each data point could be selected to show more details, including patient 
symptoms associated with that data point. All data was displayed both graphically and 
numerically, as seen in Figure 4.40. Healthcare professionals could make notes next to any 
data entry by selecting that entry. 
 
Figure 4.40: Web dashboard page 
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4.5.2.4. Web Calendar Page 
The calendar page, as seen in Figure 4.41, displayed the healthcare professional’s 
appointments. The healthcare professional could manually add appointments, but the 
appointments that the healthcare professional’s linked patients created were automatically 
displayed (if the healthcare professional accepted the appointment request). These 
appointments could be added to the healthcare professional’s email calendar too. The 
healthcare professional could select a past event and mark whether the patient attended that 
event or not, which would change the colour of the event (where red means the patient 
missed the appointment and green means the patient attended the appointment). Each 
appointment could be clicked to view extra information and add appointment notes. 
 
Figure 4.41: Web calendar page 
4.6. Testing of the Prototype 
The prototype was tested in the form of a usability study. The main goals of the usability study 
performed on the prototype were to test the usability of the prototype quantitatively, find 
major technical malfunctions in the code and receive qualitative feedback. The outcomes of 
the usability study could be implemented in future development. This test took the form of 
in-lab testing, meaning that the participants were all from the University of Cape Town - no 
actual patients or external persons were tested during this iteration of testing. The platform 
was tested using the black box testing method – a method in which the internal code of the 
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software being tested was not known to the tester. This method suited software behavioural 
testing instead of logic or algorithm testing. 
The participants involved in the study tested the mobile app by completing a set of specific 
tasks. At the completion of the set of tasks, each participant needed to complete a 
demographic questionnaire and a post-task usability questionnaire. The web app was tested 
in the same way. 
Each participant was given an explanation on the background of the project and the problem 
that the project solved. None of the participants were shown how to use the mobile app or 
web app; therefore the impartiality was maintained. Each participant spent two or three full 
days with the mobile app and glucose meter (depending on availability of the participant, the 
two smartphones with the software and the glucose meter), taking four readings per day (in 
the morning, before lunch, after lunch, and in the late afternoon). These times were chosen 
to fit into the working day so that the participants were not inconvenienced by asking them 
to record in their free time at home. The author acted as the healthcare professional 
monitoring each participant through the web app, providing feedback and answering 
questions via the messenger. After the participant completed testing the mobile app, the 
participant tested the web app by following a separate set of tasks. The web app usability test 
lasted about 30 minutes. 
The two mobile smartphones used for testing were the Hisense U962 and the Vodacom Smart 
Mini 7. Both phones came with Android 6.0, had Bluetooth capabilities and cost less than 
R1000 at the time of purchase. These phones were chosen because they were the cheapest 
smartphones which met the minimum requirements for the mobile app to function properly. 
The glucose meter used was the AccuChek Instant meter with AccuChek Instant test strips 
and SoftClix lancets. This glucose testing set was chosen because it was popular and 
affordable in South Africa. 
The questionnaire used to gauge the usability of the prototype and receive qualitative 
feedback can be seen in Appendix B. The results of the study are given below in two sections, 
one for the mobile app and one for the web app. 




There were 10 participants that were included in the study. The group was 50% male and 50% 
female, and the average age was 31.3 years. The group consisted of staff and students from 
the Division of Biomedical Engineering, University of Cape Town. The participants were all 
university graduates, including engineers, clinicians, dieticians, pharmacists and other 
healthcare professions. The small population size was deemed adequate to gauge the 
usability of the prototype and gain feedback for future development (full-scale clinical trials 
should only be implemented at a later stage of development). The group was “extremely” 
confident in the use of smartphones and computers, with 70% and 80% rating their 
confidence at the highest possible level respectively. The majority of the participants used 
health apps occasionally (80%) and health websites rarely (50%). The level of knowledge 
about diabetes was spread, with the majority (60% of participants) having an average 
knowledge. Only 40% of the participants had tested their blood glucose levels. Of all the 
participants, only 10% had ever used an app to track their blood glucose levels. The 
participants were thus technologically proficient, with an average knowledge of diabetes. This 
should be considered when analysing the data, because the target market may not have the 
same characteristics. 
Table 4.6: Demographics of participants (prototype usability study) 
1. How confident are you in using a smartphone (1 = extremely unconfident, 5 = 
extremely confident)? 
 1:  0%  2: 0%  3: 30%  4: 0%  5: 70% 
2. How confident are you in using a computer (1 = extremely unconfident, 5 = extremely 
confident)? 
 1:  0%  2: 0%  3: 20%  4: 0%  5: 80% 
3. How often do you use a health app (fitness apps, sleep apps, diet apps etc.)? 
1 = Never, 2 = Rarely (once per week), 3 =Occasionally (2-3 times per week), 4 = 
Frequently (1-2 time per day), 5 = Very Frequently (3+ times per day) 
 1:  0%  2: 10%  3: 80%  4: 0%  5: 10% 
4. How often do you use a health website to track data (fitness sites, dieting sites etc.)? 
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1 = Never, 2 = Rarely (once per week), 3 =Occasionally (2-3 times per week), 4 = 
Frequently (1-2 time per day), 5 = Very Frequently (3+ times per day) 
 1:  10% 2: 50%  3: 30%  4: 10%  5: 0% 
5. How knowledgeable are you about diabetes (1 = extremely ignorant, 5 = extremely 
knowledgeable)? 
 1:  0%  2: 20%  3: 60%  4: 0%  5: 20% 
6. How often do you test your blood glucose levels? 
1 = Never, 2 = Rarely (once per week), 3 =Occasionally (2-3 times per week), 4 = Frequently 
(1-2 time per day), 5 = Very Frequently (3+ times per day) 
 1:  60% 2: 20%  3: 0%  4: 20%  5: 0% 
7. Have you used an app to track your blood glucose levels? 
1 = Never, 2 = Rarely (once per week), 3 =Occasionally (2-3 times per week), 4 = 
Frequently (1-2 time per day), 5 = Very Frequently (3+ times per day) 
 1:  90% 2: 10%  3: 0%  4: 0%  5: 0% 
 
4.6.2. Mobile Application 
The task completion rate is recorded in Table 4.7 and the results of the usability questionnaire 
are in Table 4.8. The results seen in the tables are discussed in the paragraphs below. 
Table 4.7: Tasks to be completed (mobile prototype) 
Task Percentage of Users Who 
Completed the Task 
1. Sign-up 100% 
2. Add glucose reading reminders via the “Reminders” 
screen 
100% 
3. Record glucose data at the time specified above via the 
“Dashboard” screen 
100% 
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4. Send a message to the healthcare professional via the 
“Messenger” screen 
90% 
5. View the diabetes and pregnancy related articles via the 
“Tips” screen 
100% 
6. View your profile summary via the “Profile” screen 100% 
7. Change the notification tone via the “settings” screen 70% 
8. Send a feedback email via the “Help & Feedback” screen 70% 
9. Sign out 100% 
 
Table 4.8: Post-task questions (mobile prototype) 
1. Was the GooDMoM app easy to use (1 = extremely difficult, 5 = extremely easy)? 
 1:  0%  2: 0%  3: 50%  4: 30%  5: 20% 
2. Did you find the dashboard to be informative (1 = extremely uninformative, 5 = 
extremely informative)? 
 1:  0%  2: 0%  3: 20%  4: 50%  5: 30% 
3. Did you find the reminders to be helpful (1 = extremely unhelpful, 5 = extremely 
helpful)? 
 1:  0%  2: 40%  3: 30%  4: 20%  5: 10% 
4. Did you find the direct line of communication to the healthcare professional to be 
advantageous (1 = extremely disadvantageous, 5 = extremely advantageous)? 
 1:  0%  2: 0%  3: 20%  4: 30%  5: 50% 
5. Did you find the articles in the “tips” screen to be informative (1 = extremely 
uninformative, 5 = extremely informative)? 
 1:  0%  2: 10%  3: 20%  4: 50%  5: 20% 
6. Which feature did you think was most important to the management of GD? 
1 = The dashboard, 2 = The reminders, 3 = The messenger, 4 = The tips, 5 = none 
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 1:  50% 2: 42.9% 3: 7.1% 4: 0%  5: 0% 
7. Did you think the GooDMoM platform would help you manage your GD? 
1 = Definitely not, 2 = Probably not, 3 = Maybe, 4 = Probably, 5 = Definitely 
 1:  0%  2: 0%  3: 10%  4: 30%  5: 60% 
8. Would you use the GooDMoM platform to manage your GD? 
1 = Definitely not, 2 = Probably not, 3 = Maybe, 4 = Probably, 5 = Definitely 
 1:  0%  2: 0%  3: 20%  4: 20%  5: 60% 
 
The participants were instructed to perform the tasks shown in Table 4.7, which represented 
general tasks that would be performed by patients using the mobile app, without any 
coaching. Most of the tasks were completed by 100% of the participants, except for tasks 4, 
7 and 8 which had completion percentages of 90%, 70% and 70% respectively. Task 4 required 
patients to send a message to the healthcare professional – the messenger icon in the 
navigation bar was not seen by the one participant who did not complete this task. Task 7 
required participants to change the notification tone via the “Settings” screen and task 8 
required participants to send an email via the “Help & Feedback” screen. The notifications for 
both reminders and messages did not always work as expected, which was probably the 
reason that 30% of participants marked this task as uncompleted. The probable reason that 
the feedback email did not work was because the receiving email address (the GooDMoM 
administrator’s email address) was the same as the sending email address (the phone’s 
default email address) causing the error. This incident would not have occurred if participants 
had used their own phones with their own email addresses and, thus, required no further 
investigation. 
Most of the participants found the mobile app “adequately easy” to use (50%). There were a 
few minor navigational issues and technical malfunctions though. A few participants pointed 
out that using the back button on the Android phone produced unexpected behaviour. The 
back button would need to be configured correctly during development of the beta version. 
There were two participants who found the blood glucose entry to be “hidden”. One 
participant recommended that the mobile app should programmatically check whether the 
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glucose data has been entered or not before allowing the user to save the data and the other 
recommended that the glucose reading entry should be more prominently displayed on the 
screen. Another participant pointed out that because the new message notifications did not 
work, he did not view the messages regularly. There was also a suggestion to add the ability 
enter the different types of data (glucose, carbohydrates, weight, exercise and blood 
pressure) on separate screens. 
Of the main features of the mobile app, 50% of the participants found the dashboard “very 
informative”, 50% of the participants found the messenger “extremely advantageous” and 
50% found the tips to be “very informative”. The participants provided varied feedback about 
the reminders, rating them as either “unhelpful” (40%), “helpful” (30%), “very helpful” (20%) 
or “extremely helpful” (10%). The dashboard and the reminders were both rated as the most 
important features of the mobile app by 50% and 42.9% of participants, respectively.  
The participants enjoyed the direct line of communication with the healthcare professional, 
who answered questions, provided feedback and alerted participants to various features of 
the mobile app. However, the messages did not have a timestamp, which must be rectified 
so that users could see when messages were sent. 
The participants did not have a good experience with the reminder and message notifications, 
which did not always work. Crash reports showed that the background service in charge of 
delivering notifications was crashing. This was a technical malfunction that should be 
investigated and fixed during development of the beta version so that users can get the full 
value of appointment, medication and glucose reminders, as well as new message reminders. 
Missed reminders should also continuously notify the user until the user responds, as pointed 
out by one participant. It was suggested that the reminders screen should be made to 
replicate a calendar app, where month, week, 3-day, day and schedule views were available. 
The reminders were only shown in a schedule view at the time of writing. 
Regarding the dashboard, it was suggested that it should include a continuous weekly display 
(with horizontal scrolling). The Haemoglobin A1c (HbA1c) value should be calculated and 
displayed on the dashboard too. During data entry, the symptom selector should update the 
user’s selection on the screen so that the user could see what he or she had selected. Two 
participants thought that the nutritional data should be given more importance. One of them 
suggested that incorporating automated nutritional tips based on the glucose level readings 
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would be beneficial. The other participant recommended that functionality be added which 
would allow users to quantify what they had eaten by selecting a food type and the number 
of portions of that food type. This would be necessary because not all food showed nutritional 
information on the packaging (for example, fruits and vegetables). 
There were a few general comments, including from one participant who pointed out that 
during the sign-up process, the first name and surname should be entered separately, as 
opposed to together. There were a few comments made about the time picker on the data 
entry and reminder entry screens, which confused some participants. It was suggested that 
the time picker be discarded and replaced with a dialog which would allow the user to type 
in the time instead of selecting it. Lastly, the fact that the mobile app could only work when 
connected to the internet was an issue. An offline mode should be incorporated during 
development of the beta version. 
The results showed that 60% of the participants believed that the GooDMoM platform would 
“definitely help” them manage their GD and 60% of the participants said that they would 
“definitely use” the GooDMoM platform to manage their GD if they had the disease. Overall, 
the outcome from the usability studies was positive and placed the mobile app in a good 
position for beta development to begin. 
4.6.3. Web Application 
The task completion rate is in Table 4.9 and the results of the usability questionnaire are in 
Table 4.10. The results seen in the tables are discussed in the paragraphs below. 
Table 4.9: Tasks to be completed (web prototype) 
Task Percentage of Users Who 
Completed the Task 
1. Sign-in 100% 
2. View the patients assigned to Dr Barnard via the 
“Patients” page 
100% 
3. View the patient details of [your name] 100% 
4. View [your name]’s dashboard 100% 
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5. View the “Calendar” page 100% 
6. Send a message 100% 
 
Table 4.10: Post-task questions (web prototype) 
1. Was the GooDMoM web app easy to use (1 = extremely difficult, 5 = extremely easy)? 
 1:  0%  2: 0%  3: 20%  4: 30%  5: 50% 
2. Did you find the patient profile easy to understand and navigate (1 = extremely 
difficult, 5 = extremely easy)? 
 1:  0%  2: 0%  3: 0%  4: 60%  5: 40% 
3. Did you find the direct line of communication to the patient to be advantageous (1 = 
extremely disadvantageous, 5 = extremely advantageous)? 
 1:  0%  2: 0%  3: 10%  4: 20%  5: 70% 
4. Did you find patient details with goals and ranges to be advantageous (1 = extremely 
disadvantageous, 5 = extremely advantageous)? 
 1:  0%  2: 10%  3: 10%  4: 20%  5: 60% 
5. Did you find the dashboard to be informative (1 = extremely uninformative, 5 = 
extremely informative)? 
 1:  0%  2: 0%  3: 10%  4: 30%  5: 60% 
6. Did you find the calendar easy to understand and use (1 = extremely difficult, 5 = 
extremely easy)? 
 1:  0%  2: 0%  3: 20%  4: 30%  5: 50% 
7. Did you think the GooDMoM platform would help you to manage patients with GD (if 
you were a GD healthcare professional)? 
1 = Definitely not, 2 = Probably not, 3 = Maybe, 4 = Probably, 5 = Definitely 
 1:  0%  2: 0%  3: 10%  4: 20%  5: 70% 
Jason Leslie Collier University of Cape Town 12 January 2020 
98 
 
8. Would you use the GooDMoM platform to manage your patients with GD (if you were 
a GD healthcare professional)? 
1 = Definitely not, 2 = Probably not, 3 = Maybe, 4 = Probably, 5 = Definitely 
 1:  0%  2: 10%  3: 0%  4: 20%  5: 70% 
 
All the tasks shown in Table 4.9 were completed by 100% of the participants. These tasks 
represented the main tasks that would be performed by a healthcare professional, so it was 
a promising sign that all participants were able to complete the tasks without coaching. 
Most of the participants found the web app “extremely easy” to use (50%). One of the reasons 
given which decreased the ease of use was that there was no loading icon shown while data 
was being loaded onto the page. This gave users the impression that the web app was not 
working for a few moments until the data was loaded. Regarding the patient’s page, it was 
suggested to display the linked patients in an alphabetical list, rather than with icons and 
names. Another reason given by participants was that it was possible to deselect an icon in 
the side navigation bar which could lead to unexpected navigational errors (when viewing the 
patient’s messenger, details or dashboard). One participant suggested that it would be more 
beneficial to open a patient’s profile on the dashboard page rather than on the messenger 
page. There was a general suggestion to add the ability to change patient details from the 
web app. The ability to add a comment on the patient details page confused some 
participants, because it only allowed one comment to be added. Lastly, the data pop-up was 
not stable when participants attempted to view additional data associated with a data point 
by hovering the pointer over that data point, which should be rectified in the beta version. 
Besides the navigational issues, most participants found the patient profile to be “very easy” 
to understand and navigate (60%). 
Participants found the messenger to be “extremely advantageous” (70%), while they found 
the patient details page and the dashboard to be “extremely advantageous” (60%) and 
“extremely informative” (60%), respectively. However, there was a concern raised regarding 
the extent of the commitment of the healthcare professional to respond to the patient’s 
messages, especially during emergencies that occur during off-hours. 
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Most participants found the calendar to be “extremely easy” to understand and use (50%). 
There were some issues with the calendar, which included the inability to edit events. Two 
participants recommended that the user should be able to add an event on a specific day by 
clicking on that day’s box. Another participant suggested that while adding an event, a drop-
down box with reasons for the event should be added. 
Most participants agreed that the GooDMoM web app would “definitely help” healthcare 
professionals to manage their patients (70%) and that, if they were healthcare professionals, 
they would “definitely use” the GooDMoM web app to manage their patients (70%). This was 
a positive outcome for the alpha version which was deemed ready for beta development. 
The usability study performed on the prototype of the GD mHealth platform concludes the 
development of the alpha version of the platform. The results and feedback gained in this 
usability study will inform the development of the beta version, which will be used for 
controlled trials and field testing. The thesis continues with Chapter 5, which summarises and 
discusses the thesis as a whole. 
   




This thesis has examined the identified problem, investigated the gestational diabetes (GD) 
cycle of care in South Africa, analysed the effectiveness and the features of existing GD 
mHealth platforms and documented the design, development and testing of a new GD 
mHealth platform. The following paragraphs synthesise and discuss the information 
presented so far. 
It has been found that South African women with GD are not managed or educated about 
self-care effectively, do not self-monitor frequently enough, if at all, and, therefore, often 
succumb to various GD induced complications. The GooDMoM platform is designed to 
manage patients with GD by allowing them to monitor blood glucose readings and by offering 
an educational tool to its users, thus reducing the likelihood of GD induced complications. 
The ineffective management of GD is largely due to financial and time constraints caused by 
the regularly required outpatient services. Women with GD have to commit to outpatient 
services every 1 to 4 weeks depending on the severity of their condition and the stage of 
gestation (Mackillop et al., 2018). Even with the regularly required outpatient services, 
healthcare professionals are still not able to monitor their patients frequently enough, which 
means they cannot intervene timeously to prevent diabetes complications or provide 
feedback as often as they might like. The GooDMoM platform offers healthcare professionals 
the ability to remotely monitor their patients in real-time. This may reduce the required 
frequency of outpatient services, which may lighten the financial and time burden placed on 
patients. The platform is also designed to aid healthcare professionals in making better 
diagnoses and timeous interventions when necessary. 
The fact that that record keeping in South Africa’s public healthcare sector is mostly paper-
based contributes to the ineffectiveness of GD management practices in South Africa. Paper-
based record keeping is associated with many problems, including the possible loss of data 
due to human error, records being damaged and logistical difficulties relating to the transfer 
of data. While the private healthcare sector has made a transition to digital record keeping, 
most women with GD from both sectors are still tracking their blood glucose levels in paper-
based logbooks. Apart from the problems mentioned above, paper-based logbooks are also 
susceptible to accidental and purposeful errors in data capture. The GooDMoM platform 
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eradicates the risks associated with paper-based record keeping by seamlessly recording and 
uploading the data to the backend where it is safely stored and can be analysed by healthcare 
professionals. 
The GD cycle of care in South Africa is not as straight forward as depicted in Figure 2.1. One 
reason is that the screening methods and diagnostic criteria vary throughout South Africa, 
because each provincial health department can decide independently which diagnostic 
criteria to use. This makes determining the exact prevalence of GD in the country nearly 
impossible. In a country where there is a vast gap in healthcare quality between the public 
and private sectors, implementing the required cycle of care is easier said than done. The lack 
of resources in the public sector also means that the quality of care for patients in the public 
healthcare system may be poor. The GooDMoM platform is designed to make the 
management and treatment of GD more accessible and uniform, thus ensuring a higher 
quality of care for all patients. 
Implementing various management practices reduces the risk of complications occurring as a 
result of GD, thus forms part of the GD cycle of care. Maintaining control of blood glucose 
levels is of utmost importance when it comes to the management of GD, because good 
glycaemic control has been directly linked to reducing the risk of GD induced complications. 
Lifestyle interventions such as nutritional therapy, meeting exercise goals and managing 
weight gain also play an integral part in the management of GD. This is because diets low in 
simple carbohydrates reduce blood glucose levels, exercise improves glucose tolerance by 
improving insulin sensitivity and managing bodyweight to remain within target bodyweight 
ranges helps to maintain glycaemic control. In more extreme cases pharmacotherapy can be 
used to help maintain glycaemic control; however, it must be noted that insulin is the 
preferred medication as it does not cross the placenta to a measurable extent, as opposed to 
alternatives. The GooDMoM platform aids patients in making various lifestyle interventions 
by allowing them to track their meals, exercise, weight, blood pressure and medication. 
Many researchers had found mHealth to be a potential solution to the GD management 
problem. A systematic review and meta-analysis were performed to investigate various 
mHealth solutions for their effectiveness in aiding the management of GD. The initial search 
identified 1109 potential articles, but this was eventually narrowed down to 26 applicable 
articles of which eight were quantitative studies that were used for meta-analysis. These 
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studies were all relatively small in population size, assessed different forms of mHealth 
platforms and were deemed to contain moderate to high potential sources of methodological 
bias, so it was not possible to draw concrete conclusions from the results. Having said that, 
mHealth did offer advantages in terms of biological outcomes, maternal outcomes, perinatal 
outcomes, cognitive outcomes and economic outcomes, as described in the paragraph below. 
Many, but not all, of the outcomes which favoured mHealth were based on substantially 
heterogenous results and non-statistically significant margins.  
A notable result from the meta-analysis found that using mHealth as an intervention caused 
a statically significant decrease in overall blood glucose levels (pre-prandial and postprandial 
combined) of 0.38 mmol/L (95% CI 0.52 mmol/L to 0.23 mmol/L) when compared to a control 
group. One of the maternal outcomes showed that the intervention successfully increased 
the probability of a normal vaginal delivery by a statistically significant amount. There was 
also a statistically significant reduction in the probability of neonatal hypoglycaemia occuring. 
Non-statistically significant results found that mHealth reduced HbA1c levels, improved 
maternal outcomes by reducing the risk of emergency caesarean sections and gestational 
hypertension, improved perinatal outcomes by reducing the risk of premature births, 
improved patient compliance and reduced the frequency of outpatient services (which may 
reduce the cost of care) 
Larger randomised controls are required to confirm the findings of the systematic review. 
Based on these benefits and the fact that the evidence clearly shows that mHealth is not 
associated with harmful effects of any nature, it is acceptable to hypothesise that an mHealth 
platform can improve the management of women with GD in South Africa. 
Some of the notable benefits identified by patients using mHealth to manage their GD 
included the convenience in recording blood glucose levels digitally as opposed to paper 
logbooks, the ease of access to GD related information, the transport time saved, the 
outpatient service time saved and the ability for healthcare professionals to remotely monitor 
patients in real-time. The challenges reported by patients included the technical difficulties 
with parts of the mHealth systems and the possible loss of data privacy and security. 
The important features and functions included in existing mHealth platforms were identified 
in order to inform the design of the GooDMoM platform. To summarise the features, a GD 
mHealth platform must have the ability to automatically receive blood glucose data and 
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manually track the patient’s carbohydrates, activity duration, bodyweight, medication and 
symptoms. It must display data both graphically and numerically with colour-coded 
thresholds, send alerts and reminders to patients, educate patients on self-care and other 
diabetes related information, allow two-way communication between patients and 
healthcare professionals and transmit data to a backend for remote access by healthcare 
professionals. The platform must link the patient’s and healthcare professional’s calendar for 
consultations and store clinical and personal data on a database for real-time remote 
monitoring by healthcare professionals. These features were implemented during the design 
and development of the GooDMoM platform. 
The platform was tested in the form of a usability study. Staff and student from the Division 
of Biomedical Engineering, University of Cape Town, acted as patients and healthcare 
professionals to test the mobile app and web app, respectively. The participants included in 
the usability study were all technologically proficient, with an average to low knowledge of 
diabetes, and were qualified as engineers, clinicians, dieticians, pharmacists and other health 
related professions. The results showed that 50% of participants were males and 50% were 
females. The average age of participants was 31.3 years of age. These participants might not 
be representative of the target group, which was considered when analysing the data. 
Participants praised the UI design, especially the colour scheme and the layout of both the 
mobile app and web app. However, there was mixed feedback regarding the platform name, 
GooDMoM. Some of the notable findings from the usability study included that 50% of 
participants rated the mobile app as “easy”, 30% as “very easy” and 20% as “extremely easy” 
to use. The results showed that 50% of participants rated the dashboard as the most 
important feature, while 60% of participants said that they would “definitely use” the mobile 
app to manage their disease. Regarding the web app, 50% of participants rated the web app 
as “extremely easy” to use and 70% of participants said they would “definitely use” the 
GooDMoM platform to manage their patients with GD (if they were a GD healthcare 
professional). These results meant that the platform exceeded its requirements and placed 
the platform in a good position for further development. 
The feedback gained in the usability study will be used to guide the development of a beta 
version of the platform. This version will be ready for field testing and controlled trials. 




This chapter will conclude the thesis by presenting the main points of the thesis. It also lists 
the limitations and recommendations for further development and future research. 
The aim of this project was to develop an mHealth platform for GD self-management and for 
remote monitoring by health professionals to improve the GD cycle of care in South Africa. It 
was decided that the solution to the GD management problem would involve the use of 
mHealth. The developed mHealth platform, called GooDMoM, used a mobile app for patients 
and a web app for healthcare professionals. Research showed that such a platform could 
benefit patients both financially and timewise, by reducing the frequency of outpatient 
services required. It could also positively impact glycaemic control, maternal outcomes, 
perinatal outcomes and patient compliance. It could impact positively on the healthcare 
professionals by reducing the tediousness of their workload and allowing for remote 
monitoring of patients. If the platform were to be implemented in South Africa, it would have 
the potential to optimise the GD management process in both the public and private 
healthcare sectors in the country. 
6.1. Limitations 
A limitation identified relating to the assessment of GD management practices in South Africa 
was the fact that no GD healthcare professionals were interviewed, and no physical 
observations were made regarding the matter. The management practices and the cycle of 
care were assessed through a narrative literature review using the limited amount of research 
articles available. This limitation meant that assumptions made based on the literature review 
might not be reliable. 
The main limitations of the systematic review conducted to assess the effectiveness of 
existing GD mHealth platforms included the fact that all the studies identified were relatively 
small in population size and all of them were conducted in developed countries. These 
limitations meant that all the results obtained might not be representative of the South 
African population. 
The prototype used Firebase as a backend, which meant the prototype relied on Firebase’s 
privacy and security. This could bring the privacy and security of patients’ data into question. 
Another limitation of the prototype was that the mobile app is Android based, which excluded 
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iPhone users. Lastly, the app did not have functionality built in to support community 
healthcare workers who would benefit from a version of the mobile app which would allow 
them to monitor multiple patients. This function could benefit rural communities where 
patients might not have access to smartphones but could be monitored by a community-
based healthcare worker.  
6.2. Recommendations 
The GD management practices used in South Africa, including their flaws, need to be 
researched further. This can be done through a more user-centred approach, interviewing 
healthcare professionals directly involved in the management of GD, like obstetricians and 
midwives, and patients with GD.  
A large RCT is required to be done at a healthcare institution in South Africa to assess the 
effectiveness of mHealth in the management of diabetes. It is recommended that this trial 
consist of at least 1000 women with GD. Once the GooDMoM platform is ready for clinical 
testing, an RCT will be the next step. 
The GooDMoM platform requires its own backend to be developed with security, privacy and 
scalability in mind. This will allow administrators to be in control of the data without relying 
on a third party such as Firebase. This will also keep costs down as user numbers increase. An 
iOS version of the app is required as well as the ability to allow community-based healthcare 
workers to use the mobile app to be inclusive of all South African women with GD. 
Future developments include: 
 the creation of a South African GD information database for the tips screen, 
 the ability to automatically generate tips based on data trends and gestational 
stage, 
 the ability to offer decision support based on user data, 
 the ability to use an image reader to add medication based on the barcode, 
 the automated generation of antenatal appointments, 
 the use of blockchain to transfer data securely, 
 the integration with existing digital health platforms like MomConnect, and 
 the addition of pregnancy specific features like a contraction timer, baby kick 
counter and baby size visualiser in order to make GooDMoM comprehensive. 
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Appendix A: High-Fidelity Mock-Up Testing 
Demographics 
Name:  Click or tap here to enter text. 
Date:   Click or tap to enter a date. 
On a scale of 1 to 5 (1 = not at all confident, 5 = very confident), how would you rate your 
level of confidence in using your mobile phone or computer? 
  1☐  2☐  3☐  4☐  5☐ 
On a scale of 1 to 5 (1 = not at all knowledgeable, 5 = very knowledgeable), how would you 
rate your level of knowledge about diabetes? 
  1☐  2☐  3☐  4☐  5☐ 
How many times per day do you test your blood glucose levels? 
a. Never  
b. Rarely (once per week) 
c. Occasionally (2-3 times per week) 
d. Frequently (1-2 time per day) 
e. Very Frequently (3+ times per day) 
  1☐  2☐  3☐  4☐  5☐ 
Have you used an app to track your blood glucose levels (if you have diabetes)? 
  Yes ☐  No ☐ 
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Mobile Application High-fidelity Mock-up 
Tasks to be performed 
Please complete the tasks below and mark the tasks that you complete: 
1. Sign-up      ☐ 
Once the mock-up has opened on the home screen, click the “SIGN-UP” button to open the 
“Create Account” screen. Click the “CONTINUE” button to open the “Enter Personal 
Information” Screen. Click the “CONTINUE” button to complete the sign-up process. 
2. View the feed      ☐ 
Click on the “Feed” icon in the toolbar to open the feed screen. 
3. Log out      ☐ 
Once signed in, click on the “Settings” icon in the toolbar to open the “Settings” screen. Click 
on the “Log Out” icon or text to log out. 
4. Log in      ☐ 
On the home screen, click the “LOG IN” button to open the “Log In” screen. Click the 
“CONTINUE” button to complete the log in process. 
5. Add a reminder (appointment, medication or glucose reading) ☐ 
Once logged in, click on the “Reminders” icon in the toolbar to open the “Add Reminder” 
screen. Click on the “ADD” button to add the reminder. Click on the “Okay” text or on the tick 
button when the confirmation pop-up displays. 
6. Enter data (glucose reading, meal, carbs, activity, bodyweight, medication) ☐ 
Once logged in, click on the “Data” icon in the toolbar to open the “Data Entry” screen. 
7. Synchronise data with glucose meter on data entry screen  ☐ 
Click on the synchronise icon or the “Glucose” text near the top of the data entry screen to 
synchronise with the Bluetooth enabled glucose meter. Click on the “Okay” text or on the tick 
button when the confirmation pop-up displays. Scroll down and click the “ADD” button to add 
the data. Click on the “Okay” text or on the tick button when the confirmation pop-up displays. 
8. Send a message to healthcare professional   ☐ 
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Once logged in, click on the “Messenger” icon in the toolbar to open the messenger screen in 
order to message a healthcare professional. Click on the send arrow near the bottom right of 
the screen to send a message. Click anywhere on the screen to dismiss the “sent” pop-up. 
9. View “Tips and tricks” articles    ☐ 
Once logged in, click on the “Tips” icon in the toolbar to open the “Tips and tricks” screen. 
Scroll down to view more articles. 
10. Go to settings      ☐ 
Once logged in, click on the “Settings” icon in the toolbar to open the “Settings” screen. 
a. View profile     ☐ 
On the “Settings” screen, click the “PROFILE” button to view profile. 
b. Change profile picture    ☐ 
On the “settings” screen or the profile screen, click on the camera icon to view change or 
remove a profile picture. 
  




1. On a scale of 1 to 5 (1 = negative, 5 = positive), how would you rate the ease of your 
experience with the GoodMoM app? 
  1☐  2☐  3☐  4☐  5☐ 
2. On a scale of 1 to 5 (1 = unsuitable, 5 = suitable), how suitable did you think the 
GooDMoM name was for the platform? 
  1☐  2☐  3☐  4☐  5☐ 
3. On a scale of 1 to 5 (1 = unattractive and inappropriate, 5 = attractive and appropriate), 
how would you rate the colour scheme of the app? 
  1☐  2☐  3☐  4☐  5☐ 
4. On a scale of 1 to 5 (1 = cluttered and confusing, 5 = well-spaced and easily 
understandable), how would you rate the layout of the app? 
  1☐  2☐  3☐  4☐  5☐ 
5. Did you have any navigation issues? Yes ☐ No ☐ 
 If so, please briefly describe your issue:  
 Click or tap here to enter text. 
6. Which feature did you think is most important? 
1. The feed (graphically and statistically displays results) 
2. The reminders (remind the user about appointments medication and glucose testing) 
3. The data capture (automatically capture blood glucose data and manually capture the 
rest) 
4. The messenger (directly communicate with a healthcare professional) 
5. The tips and tricks 
  1☐  2☐  3☐  4☐  5☐ 
7. Were there any features you did not understand?  Yes ☐ No ☐ 
 If so, please briefly describe which one and why:  
 Click or tap here to enter text. 
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Web Application High-fidelity Mock-up 
Tasks to be performed 
Please complete the tasks below and mark the tasks that you complete: 
1. Log in      ☐ 
Once the mock-up has opened on the home screen, click the “LOG IN” button to open the “Log 
In” screen. Click the “LOG IN” button to complete the log in process. 
2. View the patient database     ☐ 
Click on “PATIENTS” anywhere on the screen to open up the “Patient Database” where the 
doctor can access his patients. 
3. View a specific patient     ☐ 
Click on a specific patient to open their profile. 
4. View the patient’s personal details, patient history and dashboard ☐ 
On the patient’s profile, use the navigation bar on the left to view the patient’s “PERSONAL 
DETAILS”, “PATIENT HISTORY” (can scroll down to view more) and “BLOOD GLUCOSE LEVELS”. 
5. View the messenger     ☐ 
Click on “MESSENGR” anywhere on the screen to open up the “Messenger” where the doctor 
can communicate with linked patients. 
6. View the calendar     ☐ 
Click on “Calendar” anywhere on the screen to open up the “Calendar” where the doctor’s 
appointments will be displayed (linked to patient’s mobile app). 
7. View the Home screen     ☐ 
On any screen, click on the GooDMoM symbol in the top left to return to “Home” 
  




1. On a scale of 1 to 5 (1 = negative, 5 = positive), how would you rate the ease of your 
experience with the GoodMoM web app? 
  1☐  2☐  3☐  4☐  5☐ 
2. On a scale of 1 to 5 (1 = cluttered and confusing, 5 = well-spaced and easily 
understandable), how would you rate the layout of the web app? 
  1☐  2☐  3☐  4☐  5☐ 
3. Did you have any navigation issues? Yes ☐ No ☐ 
 If so, please briefly describe your issue:  
 Click or tap here to enter text. 
4. Was there any functionality you believed needed to be added? Yes ☐ No ☐ 
 If so, please briefly describe what: 
 Click or tap here to enter text. 
5. If you have any other comments, please describe them below: 
 Click or tap here to enter text. 
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Appendix B: Prototype Testing 
Demographics 
Name:   Click or tap here to enter text. 
Date:   Click or tap to enter a date. 
Age:  Click or tap here to enter text. 
Gender: Choose an item. 
1. How confident are you in using a smartphone? 
a. ☐ Extremely confident  
b. ☐ Very confident  
c. ☐ Adequately confident 
d. ☐ Unconfident  
e. ☐ Extremely unconfident 
2. How confident are you in using a computer? 
a. ☐ Extremely confident  
b. ☐ Very confident  
c. ☐ Adequately confident 
d. ☐ Unconfident  
e. ☐ Extremely unconfident 
3. How often do you use a health app (fitness apps, sleep apps, diet apps etc.)? 
a. ☐ Very Frequently (3+ times per day) 
b. ☐ Frequently (1-2 time per day) 
c. ☐ Occasionally (2-3 times per week) 
d. ☐ Rarely (1 time per week or less) 
e. ☐ Never 
4. How often do you use a health website to track data (fitness sites, dieting sites etc.)? 
a. ☐ Very Frequently (3+ times per day) 
b. ☐ Frequently (1-2 time per day) 
c. ☐ Occasionally (2-3 times per week) 
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d. ☐ Rarely (1 time per week or less) 
e. ☐ Never 
5. How knowledgeable are you about diabetes? 
a. ☐ Extremely knowledgeable  
b. ☐ Very knowledgeable  
c. ☐ Adequately knowledgeable 
d. ☐ Ignorant  
e. ☐ Extremely ignorant 
6. How often do you test your blood glucose levels? 
a. ☐ Very Frequently (3+ times per day) 
b. ☐ Frequently (1-2 time per day) 
c. ☐ Occasionally (2-3 times per week) 
d. ☐ Rarely (1 time per week or less) 
e. ☐ Never  
7. Have you used an app to track your blood glucose levels? 
a. ☐ Very Frequently (3+ times per day) 
b. ☐ Frequently (1-2 time per day) 
c. ☐ Occasionally (2-3 times per week) 
d. ☐ Rarely (1 time per week or less) 
e. ☐ Never 
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Mobile Application Prototype 
Tasks to be performed 
Please complete the tasks below and mark the tasks that you complete: 
1. Sign-up      ☐ 
When asked to enter your healthcare professional’s surname, user ID and type, enter 
“Barnard”, “1” and obstetrician respectively. For your diabetes type, select “Gestational 
Diabetes”. Calculate your due date via the “Last Period” method, with the first day of last 
period being 1 March 2019 and the cycle length being 28 days. 
2. Add glucose reading reminders via the “Reminders” screen  ☐ 
(1) Add a morning glucose reading reminder which repeats every 1 day for 3 counts at 09:30 
starting on day 1 of testing. (2) Add a pre-lunch glucose reading reminder which repeats every 
1 day for 3 counts at 12:30 starting on day 1 of testing. (3) Add a post-lunch glucose reading 
reminder which repeats every 1 day for 3 counts at 13:30 starting on day 1 of testing. (4) Add 
an afternoon glucose reading reminder which repeats every 1 day for 3 counts at 16:30 
starting on day 1 of testing. 
3. Record glucose data at the time specified above via the “Dashboard” screen ☐ 
Use the glucose meter to measure your blood glucose levels. For each data entry, record your 
meal data, activity data, weight data, medication data, blood pressure data and symptoms 
ONLY if relevant since the last entry. 
4. Send a message to the healthcare professional via the “Messenger” screen ☐ 
Reply to the healthcare professional’s message.  
5. View the diabetes and pregnancy related articles via the “Tips” screen ☐ 
Open one of the articles which interest you. 
6. View your profile summary via the “Profile” screen  ☐ 
Can you see your calculated BMI as well as your glucose goals entered by your healthcare 
professional? 
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7. Change the notification tone via the “settings” screen  ☐ 
8. Send a feedback email via the “Help & Feedback” screen  ☐ 
Once all tasks have been completed, please email the admin saying, “all tasks have been 
completed”. 
9. Sign out      ☐ 
Please enter any additional comments here: 
Click or tap here to enter text. 
  




1. Was the GooDMoM app easy to use? 
a. ☐ Extremely easy  
b. ☐ Very easy  
c. ☐ Adequately easy 
d. ☐ Difficult  
e. ☐ Extremely difficult 
Please describe any issues with the ease of use (navigation, layout, bugs etc.):  
Click or tap here to enter text. 
2. Did you find the dashboard to be informative? 
a.  ☐ Extremely informative  
b. ☐ Very informative  
c. ☐ Adequately informative 
d. ☐ Uninformative  
e. ☐ Extremely uninformative 
3. Did you find the reminders to be helpful? 
a.  ☐ Extremely helpful  
b. ☐ Very helpful  
c. ☐ Adequately helpful 
d. ☐ Unhelpful  
e. ☐ Extremely unhelpful 
4. Did you find the direct line of communication to the healthcare professional to be 
advantageous? 
a.  ☐ Extremely advantageous  
b. ☐ Very advantageous  
c. ☐ Adequately advantageous 
d. ☐ Disadvantageous  
e. ☐ Extremely disadvantageous 
5. Did you find the articles in the “tips” screen to be informative? 
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a. ☐ Extremely informative  
b. ☐ Very informative  
c. ☐ Adequately informative 
d. ☐ Uninformative  
e. ☐ Extremely uninformative 
6. Which feature did you think is most important to the management of gestational 
diabetes? 
a. ☐ The dashboard 
b. ☐ The reminders  
c. ☐ The messenger 
d. ☐ The tips  
e. ☐ None 
If you did not like any of the features, please explain why:  
Click or tap here to enter text. 
7. Did you think the GooDMoM platform would help you manage your gestational 
diabetes? 
a. ☐ Definitely  
b. ☐ Probably  
c. ☐ Maybe 
d. ☐ Probably not 
e. ☐ Definitely not 
8. Would you use the GooDMoM platform to manage your gestational diabetes? 
a. ☐ Definitely  
b. ☐ Probably  
c. ☐ Maybe 
d. ☐ Probably not 
e. ☐ Definitely not 
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Do you have any other comments? If so, please add them here: 
Click or tap here to enter text. 
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Web Application Prototype 
Tasks to be performed 
Please complete the tasks below and mark the tasks that you complete: 
1. Sign-in      ☐ 
Go to https://gd-mhealth.firebaseapp.com in your web browser. You will be using Dr Christian 
Barnard’s profile (this is a fake profile for testing purposes) to complete these tasks. The email 
is doctor@mail.com and the password is “abc123” to sign-in to this profile. 
2. View the patients assigned to Dr Barnard via the “Patients” page ☐ 
Open the “Patients” page to view the list of patients assigned to you. Click on [your name] to 
enter [your name]’s profile. 
3. View the patient details of [your name]   ☐ 
View [your name]’s patient details by clicking on “Patient Details” on the side navigation. Edit 
[your name]’s target weight and add a comment saying, “I have viewed the details” and save 
it. 
4. View [your name]’s dashboard    ☐ 
View [your name]’s dashboard by clicking on “Dashboard” on the side navigation. Change the 
time display to “Day” and choose a date on which [your name] recorded glucose data. Hover 
your mouse over the highest glucose recording and view the carbs and symptoms that may be 
associated with that recording. Go to the “Full Gestation” time period and refresh the glucose 
chart to display “Fasting” and “Postprandial” glucose readings. 
5. View the “Calendar” page     ☐ 
Open the “Calendar” page and click on one of the events in May to display more details. Add 
an event for [your name] on today’s date titled “Usability Test”. Verify that it appears on the 
calendar. 
6. Send a message     ☐ 
Send a message to Jason Collier once you have completed the tasks saying, “Tasks completed”. 
Do this by opening Jason Collier’s profile and clicking on “Messenger” on the side navigation 




1. Was the GooDMoM web app easy to use? 
f. ☐ Extremely easy  
g. ☐ Very easy  
h. ☐ Adequately easy 
i. ☐ Difficult  
j. ☐ Extremely difficult 
Please describe any issues with the ease of use (navigation, layout, bugs etc.):  
Click or tap here to enter text. 
2. Did you find the patient profile easy to understand and navigate? 
f.  ☐ Extremely easy  
g. ☐ Very easy  
h. ☐ Adequately easy 
i. ☐ Difficult  
j. ☐ Extremely difficult 
3. Did you find the direct line of communication to the patient to be advantageous? 
f.  ☐ Extremely advantageous  
g. ☐ Very advantageous  
h. ☐ Adequately advantageous 
i. ☐ Disadvantageous  
j. ☐ Extremely disadvantageous 
4. Did you find patient details with goals and ranges to be advantageous? 
a.  ☐ Extremely advantageous  
b. ☐ Very advantageous  
c. ☐ Adequately advantageous 
d. ☐ Disadvantageous  
e. ☐ Extremely disadvantageous 
5. Did you find the dashboard to be informative? 
a.  ☐ Extremely informative  
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b. ☐ Very informative  
c. ☐ Adequately informative 
d. ☐ Uninformative  
e. ☐ Extremely uninformative 
6. Did you find the calendar easy to understand and use? 
a.  ☐ Extremely easy  
b. ☐ Very easy  
c. ☐ Adequately easy 
d. ☐ Difficult  
e. ☐ Extremely difficult 
If you did not like any of the features, please explain why:  
Click or tap here to enter text. 
7. Did you think the GooDMoM platform would help you to manage patients with 
gestational diabetes (if you were a gestational diabetes healthcare professional)? 
f. ☐ Definitely  
g. ☐ Probably  
h. ☐ Maybe 
i. ☐ Probably not 
j. ☐ Definitely not 
8. Would you use the GooDMoM platform to manage your patients with gestational 
diabetes (if you were a gestational diabetes healthcare professional)? 
f. ☐ Definitely  
g. ☐ Probably  
h. ☐ Maybe 
i. ☐ Probably not 
j. ☐ Definitely not 
Do you have any other comments? If so, please add them here: 
Click or tap here to enter text. 
 
